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Abstract	  
Generation of neutralising antibodies with broad specificity would be one of the 
effective approaches to control HIV-1 spread. It is clear that a method that allows rapid 
generation of neutralising antibodies is needed. This project aims at developing a novel 
approach to rapidly access human anti-HIV-1 antibodies in vitro by using ribosome 
display and selection from DNA libraries of HIV-1 patients. 
 
Two single-chain antibody libraries (M325 and K530) were constructed from two 
HIV-1 long-term non-progressors, whose sera showed cross-neutralising activities 
against various HIV-1 strains across a range of clades. In each library, total RNA was 
extracted from blood of each donor and used to synthesise cDNA. Families of 4 κ light 
chains, 9 λ light chains and 8 heavy chains were generated by using RT-PCR 
amplification. These fragments were then assembled with all possible combinatorial 
pairs to form diversified repertories in the form of VL-link-VH-partial CH. 
 
Both libraries were subjected to ribosome display for in vitro selection of functional 
antibodies. Ribosome display is a cell-free technique used to generate proteins that can 
bind to an immobilised antigen. During this process, the translated proteins are 
associated with their mRNAs, enabling a simultaneous selection of functional proteins 
and their gene. The employment of ribosome display facilitated rapid screening of two 
large libraries against recombinant gp120 (generated from patient K530).  
 
Ten selected antibodies were expressed as single-chain variable fragments in 
Escherichia. coli. High activity antibodies were purified from both total cell extract 
and periplasmic fraction using optimised expression and purification conditions. These 
antibodies showed various binding activities against gp120 and modest neutralising 
activities against a laboratory HIV-1 clone. Remarkably, an identical CDR3 sequence 
was observed in a number of selected antibodies from the two separated libraries, 
indicating a strong selection of functional antibodies by ribosome display.  
 
This study has provided a novel, in vitro method to select potentially neutralising 
monoclonal antibodies against HIV-1.  
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1.1 AIDS/HIV Background  
 
 
1.1.1 The epidemic of AIDS 
 
The human immunodeficiency virus (HIV) is a member of the genus Lentivirus in the 
Retroviridae family that causes acquired immune deficiency syndrome (AIDS). The 
Joint United Nations Programme on HIV/AIDS (UNAIDS) reported that more than 25 
million people have died from AIDS in the world, and an estimate of 33.3 million 
people have been infected by HIV, including 2.6 million new cases in 2009 (UNAIDS, 
2010). Although antiretroviral therapy (ART) has greatly increased the survival rate 
and quality of life among infected individuals, only 5.2 million people can access, 
leaving 65% of the population who still need treatment today (UNAIDS, 2010). 
Moreover, an effective vaccine is still an elusive goal, despite considerable research 
efforts that have been attempted over the past three decades. 
 
 
1.1.2 The discovery of HIV 
 
The initial articles related to AIDS were published by the Centres for Disease Control 
and Prevention (CDC) in 1981 (CDC, 1981a, CDC, 1981b). AIDS symptoms were 
originally noticed in homosexual males. Subsequently, similar symptoms were 
observed in haemophiliacs, intravenous drug users and heterosexual Haitians in the 
following years (Selik et al., 1984). The term AIDS designated by the CDC was first 
used in 1982, when 593 people were diagnosed with the syndrome, with 243 deaths 
(CDC, 1982). 
 
HIV was first isolated in 1983, when Barré-Sinoussi and her colleagues at the Pasteur 
Institute recovered a virus from the lymph node of a French patient who had persistent 
generalised lymphadenopathy, a disease that was suspected to be associated with AIDS 
(Barre-Sinoussi et al., 1983). This virus was later called lymphadenopathy-associated 
virus (LAV) by Montagnier (Montagnier et al., 1984b), who shared the Nobel Prize in 
Physiology or Medicine 2008 with Barré-Sinoussi for their discovery of HIV. LAV 
contained reverse transcriptase (RT) activity and shared some characteristics of human 
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T-cell leukaemia virus (HTLV) (Barre-Sinoussi et al., 1983), which made some early 
investigators to believe that HTLV was isolated from AIDS patients (Gallo et al., 
1983). However, LAV grew to substantial titre in CD4+ cells and killed them, instead 
of immortalising the lymphocytes in culture (Montagnier et al., 1984a). In early 1984, 
Gallo and associates isolated another human retrovirus from the peripheral blood 
mononuclear cells (PBMCs) of AIDS patients (Gallo et al., 1984). This virus was 
named HTLV-III but later was confirmed as the same as LAV (Chang et al., 1993). At 
the same time, Levy and co-workers reported their identification of retroviruses from 
different AIDS groups, as well as from asymptomatic individuals (Levy et al., 1984). 
These viruses were named the AIDS-associated retroviruses (ARVs), and it was the 
first time a healthy carrier state for the AIDS virus was observed. The three prototype 
viruses, LAV, HTLV-III and ARV, were soon recognised as belonging to the same 
group of retroviruses, which was given a separate name HIV by the International 
Committee on Taxonomy of Viruses in 1986 (Coffin et al., 1986). 
 
A second AIDS virus was later discovered from patients in West Africa, particularly 
the Cape Verde Islands and Senegal (Clavel et al., 1986). This virus differs by more 
than 55% from the previously isolated HIV-1 strains, and was designated as HIV-2. 
The genome of HIV-2 is similar to that of HIV-1 (figure 1.1), except that the viral 
protein U (vpu) gene is restricted to HIV-1 and the viral protein X (vpx) gene is 
restricted to HIV-2 (Cohen et al., 1988, Tristem et al., 1990). HIV-2 is less pathogenic 
than HIV-1. Individuals infected by HIV-2 usually survive longer without showing the 
disease, maintain a higher level of CD4+ cells and show a reduced rate in transmission 
than those infected with HIV-1 (Kanki et al., 1992, Reeves and Doms, 2002, Donnelly 
et al., 1993). Therefore, most of the studies have been focused on HIV-1. 
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Figure 1.1 Genomic maps of HIV-1 and HIV-2  
The genome of HIV-1 and HIV-2 are very similar, except that the vpu gene is 
restricted to HIV-1 and the vpx gene is restricted to HIV-2.  
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1.1.3 The heterogeneity of HIV 	  
HIV is featured by its extensive heterogeneities in biology and serology, which is 
reflected by the variable genetic sequences of the virus. The viral RT is very error 
prone during replication (Preston et al., 1988, Roberts et al., 1988). Research by Coffin 
indicated that HIV replicates on almost a daily basis and up to 10 base changes in the 
HIV genome can occur in a single replicative cycle (Coffin, 1995). In addition, 
recombination of two or more different HIV strains may occur in a single cell, 
generating a mosaic DNA genome (McCutchan, 2006). The total viral genomic 
sequences can differ by 6% to 10% among different individuals (Levy, 2007). The high 
mutation rate and diverse genome give rise to enormous changes on viral phenotype, 
especially the regulatory and envelope proteins (Martins et al., 1991). The envelope 
protein presented on the surface of HIV can vary up to 35% between subtypes and 20% 
within subtypes (Gaschen et al., 2002).  
 
Based on the full-length viral genome sequencing and amino acid analysis, HIV-1 can 
be classified into four groups: the “major” group M, the “Outlier” group O, a “non-
M/non-O” group N and a recently discovered group P (Robertson et al., 2000, Plantier 
et al., 2009). More than 90% of HIV-1 infections belong to HIV-1 group M, which can 
be further divided into at least nine subtypes (clades): A, B, C, D, F, G, H, J and K 
(figure 1.2). Each subtype differs from the others by at least 15 to 20% in amino acid 
sequences in the group-specific antigen (Gag) and envelope glycoprotein (Env) region 
(Robertson et al., 2000). In some cases, recombinant viruses become epidemiologically 
important branches and they are called circulating recombinant forms (CRFs) 
(McCutchan, 2006). Viruses recombining from four or more subtypes are called 
complex (cpx).  Currently 16 CRFs have been recognised from the group M (Peeters et 
al., 2003, Robertson et al., 2000). Two previously designated HIV-1 subtypes, E and I, 
were renamed CRF_01AE and CRF_04cpx respectively when they were identified 
recombinants (Anderson et al., 2000). The subtypes responsible for the majority of 
global infections are A, B, C, D, CRF01_AE and CRF02_AG (Robertson et al., 2000). 
Group O individuals were initially found in Cameroon (Peeters et al., 1997) and 
accounts for about 25% of viral isolates from Cameroon (Ayouba et al., 2001). Group 
N infections were only found in a few cases in Cameroon and this group appears to be 
more similar to chimpanzee simian immunodeficiency virus (SIV) than other HIV-1 
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groups (Peeters et al., 2003). A new group of HIV-1 isolates (group P) was identified 
from a Cameroonian woman in 2009 (Plantier et al., 2009). This virus is closely related 
to gorilla SIV and genetically distinct from HIV-1 groups M, N and O. 
 
Although HIV-2 is very rare compared to HIV-1 and is located in a few countries in 
West Africa, eight distinct groups of HIV-2 (A to H) have been identified. Group A 
and B account for the most prevalence of HIV-2, while the other six groups have only 
one representative infection (Chen et al., 1997, Yamaguchi et al., 2000, Damond et al., 
2004). Differences between HIV-2 groups are nearly as much as that between the M, 
N, O and P groups of HIV-1, with up to 25% variation in the amino acid sequences of 
the Gag, Polymerase (Pol) and Env (Zagury et al., 1988).  
 
 
 
 
Figure 1.2 The different levels of HIV classification 
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1.1.4 The origin of HIV 	  
Based on molecular evolutionary studies of primate lentiviruses, it has been proposed 
that HIV-1 came into the human population from primates about 30 to 100 years ago 
(Sharp et al., 2001). Other investigators argued that this virus could have appeared in 
human population earlier (Leigh Brown and Holmes, 1994). Although there are several 
explanations and hypothesises for the origin of HIV-1 presented, the most common and 
generally accepted idea is that HIV-1 was derived from SIV found in chimpanzees 
(Gao et al., 1999). It is generally proposed that the HIV-1 groups M, N and O entered 
the human population by three separate cross-species transmissions of chimpanzee SIV 
(Huet et al., 1990, Corbet et al., 2000). Studies on recently isolated SIV samples 
provided evidence that group M most likely originated from chimpanzees in South 
Eastern Cameroon, while group N originated from chimpanzees in South Central 
Cameroon (Keele et al., 2006). By contrast, no direct evidence has been found to link a 
SIV isolate to HIV-1 group O yet (Keele et al., 2006). Recently, viruses isolated from 
the Western Lowland Gorilla resembled group O (Van Heuverswyn et al., 2006), 
suggesting that gorillas may be involved in the transmission of SIV to humans.  
  
HIV-2 is genetically close to SIV isolates in monkeys in West Africa, especially sooty 
mangabeys (Marlink, 1996). It is believed that the two most prevalent groups A and B 
were originated from sooty mangabeys from Ivory Coast (Santiago et al., 2005). 
 
 
1.1.5 The structure of HIV 
 
HIV exists as roughly spherical shape (figure 1.3) with a diameter of approximately 
100 to 120 nm (Kuznetsov et al., 2003). The viral proteins are designated with 
numbers reflecting the protein sizes in kilodaltons (kDa). A mature virus is surrounded 
by a lipid bilayer membrane, on which about 70 trimeric Envs are embedded (Chan et 
al., 1997, Kuznetsov et al., 2003). The Env consists of an external surface 
glycoprotein, gp120 and a transmembrane glycoprotein, gp41, both derived from a 160 
kDa precursor glycoprotein, gp160 (McCune et al., 1988). 
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Three structural Gag proteins are located inside the virus: matrix (MA, p17), capsid 
(CA, p24) and nucleocapsid (NC, p7) (Freed, 1998). The MA forms an inner shell just 
inside the viral membrane; recent evidences suggested that MA might be a regulatory 
protein involved in enhancing HIV pathogenesis (Li et al., 2010). The CA protein 
constitutes a conical core inside MA, coating two identical copies of single-stranded 
RNA. The NC interacts with viral RNA and is required for RNA splicing and RNA 
encapsidation (Zhang and Barklis, 1995). All these three Gag proteins are cleaved from 
a polyprotein precursor, p55, by the viral protease (PR) (Mervis et al., 1988, Kohl et 
al., 1988).  
 
The two copies of RNA are located inside the capsid (p24) and are linked together at 
the 5’ end (Jossinet et al., 1999). The dimerisation initiation site (DIS) on the linkage is 
a hairpin structure and plays a role in virus maturation and recombination 
(Balakrishnan et al., 2003). The 5’ and 3’ end of HIV RNA encode a long terminal 
repeat (LTR) sequence, which regulates integration and virus replication (Temin, 1981, 
Vicenzi et al., 1994). There are three enzymes closely associated with the viral RNA: 
the reverse transcriptase (RT, p66, p51), the protease (PR, p10) and the integrase (IN, 
p32). RT is also called RNA-dependent DNA polymerase, and plays an important role 
in viral replication by transcribing the RNA into double-stranded DNA (Baltimore, 
1970). The PR cleaves viral proteins into their functional forms. The IN incorporates 
the viral DNA into host cell chromosomal DNA (Brown et al., 1989). All three 
enzymes are cleaved from Pol precursor polyprotein (Jacks et al., 1988).  
 
HIV also has two regulatory proteins, transactivator of transcription (Tat, p14) and 
regulator of virion expression (Rev, p19), which are essential for viral replication 
(Fisher et al., 1986, Sodroski et al., 1986). Tat is a major protein that up-regulates HIV 
replication. It also induces T cell apoptosis (Westendorp et al., 1995) and co-receptors 
expression on cell surfaces (Huang et al., 1998), and blocks natural killer (NK) cell 
activities (Zocchi et al., 1998). Rev affects viral protein expression by regulating 
messenger RNA (mRNA) splicing and transporting unspliced mRNA to the cytoplasm 
of cell for protein translation (Malim et al., 1988, Malim et al., 1989).  
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Figure 1.3 Structure of HIV  
Trimeric glycoprotein gp120 and gp41 are embedded on HIV surface membrane. From 
outside to viral centre are structural proteins matrix (MA, p17) and capsid (CA, p24). 
Inside CA are two copies of single-stranded RNA, linked at their 5’ end by 
dimerisation initiation site (DIS). Structure protein nucleocapsid (NC, p7) and three 
enzymes reverse transcriptase (RT, p66, p51), protease (PR, p10) and integrase (IN, 
p32) are presented inside the viral core.  
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In addition, two accessory proteins closely associated with the core, namely negative 
factor (Nef, p27) and virus infectivity factor (Vif, p23). Nef regulates virus replication 
(Garcia and Miller, 1991) and activates cellular proteins (Sawai et al., 1994) while Vif 
increases virus infectivity (Strebel et al., 1987) and cell-to-cell transmission (Fisher et 
al., 1987), and helps in proviral DNA synthesis and assembly (Borman et al., 1995). 
Other accessory proteins include viral protein R (Vpr, p15), viral protein U (Vpu, p16, 
only presents on HIV-1) and viral protein X (Vpx, p15, only presents on HIV-2), 
which mainly help in virus replication, virus release and viral infectivity, respectively 
(Greene and Peterlin, 2002). 
 
 
1.1.6 The life cycle of HIV 
 
The life cycle of HIV starts by gp120 attaching to its cellular receptor cluster of 
differentiation 4 (CD4) (Dalgleish et al., 1984). The CD4 receptor is expressed on the 
surface of T helper cells, macrophages and dendritic cells. It has four immunoglobulin 
like domains (D1 to D4), in which D1 region is involved in HIV binding (Arthos et al., 
1989). Gp120 consists of five variable domains (V1-V5) with five constant domains 
(C1-C5), and the outer surface of gp120 is heavily glycosylated (Wei et al., 2003). A 
major binding site has been identified to locate on C4 domain near the 3’ end of gp120 
(Lasky et al., 1987, Sweet et al., 1991). Studies showed that other discontinuous, 
conserved regions also interact with the binding sites on CD4 (Thali et al., 1993).  
 
After attachment to the CD4 protein, a conformational change occurs on the gp120, 
leading to interactions between the gp120 and its co-receptors (figure 1.4). HIV 
generally needs chemokine receptors for additional attachment, the most common ones 
are CCR5 for macrophage-tropic isolates (Cheng-Mayer et al., 1997) and CXCR4 for 
T cell line-tropic isolates. The viruses that use these co-receptors are referred to as R5 
and X4 viruses, respectively (Berger et al., 1998). The co-receptor binding and tropism 
are mainly determined by the V3 loop of gp120, as well as the V1 and V2 regions 
(Hartley et al., 2005). Mutation studies showed that as few as three amino acid changes 
in the V3 loop were sufficient to change R5 virus to X4 virus (Shioda et al., 1992). The 
attachment to co-receptors brings the virus closer to the cell, and exposes gp41 to a 
fusion domain on the cell (Sattentau and Moore, 1991).  
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Figure 1.4 A schematic illustration of HIV entry 
HIV entry can be divided into three steps: (1) gp120 attaches to CD4 receptor; (2) 
conformational change in gp120, which induces gp120 to bind to co-receptor, CCR5 or 
CXCR4; (3) structural rearrangement in gp41 allows the virus and cell membrane 
fusion and ultimately entry of the virus into the target cell. 
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Virus and CD4+ cell fusion is a critical step in HIV life cycle. The fusion between viral 
and the host cellular membranes allows the entry of viral capsid into the cell (Pascual 
et al., 2005). Mutation studies indicated that several domains of gp120 (the V1/V2 
domain, the V3 loop and the C4 domain) and gp41 could contribute to membrane 
fusion (Sullivan et al., 1993, Page et al., 1992, Suphaphiphat et al., 2007). However, 
the exact mechanism for the nucleocapsid entry remains unclear. Hypotheses include 
intermixing of the outer lipid membranes of the virus and the cell (i.e. semifusion) 
(Haywood, 1994), and involvement of Gag protein in viral core entry (Spearman et al., 
1994). 
 
After HIV has entered the cell, the reverse transcription of viral RNA starts by 
formation of a RNA-DNA hybrid helix (Baltimore, 1970), followed by the synthesis of 
a second strand of cDNA by RT. The double-stranded viral DNA is then transported to 
the cell nucleus, where it is integrated into host cell DNA by viral integrase (IN) 
(Brown et al., 1989, Bushman et al., 1990). The integrated viral DNA is known as 
proviral DNA, and it can be dormant for a long time. Upon activation, the proviral 
DNA is transcribed to generate mRNA by the host cell RNA polymerase II. The 
primary mRNA transcripts contain multiple introns and can be processed to yield more 
than 30 alternative mRNAs by various levels of splicing (Schwartz et al., 1990). 
Doubly spliced mRNA can translate to the major regulatory proteins, particularly Nef, 
Tat and Rev (Greene and Peterlin, 2002); partially spliced mRNA has the potential to 
express the Env precursor (gp160), Vif, Vpu and Vpr; the unspliced mRNA can be 
expressed as Gag and Gag-Pol precursor proteins or serve as the genomic RNA. The 
gp120 and gp41 is in fact generated by an endoprotease cleavage of gp160 precursor 
before transportation to the plasma membrane of the cell (Hallenberger et al., 1992). 
The two nascent viral RNA are also transported to the plasma membrane with Gag and 
Gag-Pol precursor proteins. Assembly and package of the virion takes place by 
budding through plasma membrane of the cell (Freed and Martin, 1996, Booth et al., 
2006). During this process, the Gag and Gag-Pol precursor proteins are cleaved by 
protease to form the proper HIV proteins, which result in a mature virion (figure 1.5).  
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Figure 1.5 The life cycle of HIV  
The life cycle of HIV includes multiple steps: (1) the viral surface envelope protein 
(purple cycle) attaches to cellular receptors (blue block); (2) the viral membrane fuses 
to the cell membrane; (3) the viral nucleoid enters the cell; (4) the viral RNA is reverse 
transcribed into double-strand DNA (green line) by RT (green cycle); (5) the viral 
DNA is integrated into host chromosome (orange straight line) by IN; (6) the proviral 
DNA is transcribed into mRNA; (7) the mRNA translates to various viral proteins 
(precursors); (8) viral RNA and envelope protein are assembled at the cell membrane; 
(9) a fully functional mature virion is produced. 
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1.1.7 The cell-mediated responses of HIV infection 
 
HIV infection is controlled by anti-HIV-specific activities from both CD8+ and CD4+ 
cells. The HIV-specific CD8+ T cell response appears within the first few weeks of 
HIV infection, and expands rapidly to 10% of the total circulating CD8+ T cells when 
the viral load peaks (Borrow et al., 1994, Wilson et al., 2000). CD8+ T cells play an 
important role in controlling viral replication and disease progression. Clinical studies 
showed that patients with stronger CD8+ cytotoxic T lymphocyte (CTL) responses had 
a slower disease progression compared to those with lower CTL responses (Musey et 
al., 1997). Furthermore, studies on asymptomatic long-term non-progressors (LTNPs) 
(Rinaldo et al., 1995) and HIV-exposed but uninfected Gambian women (Rowland-
Jones et al., 1995) revealed the strong association between their lack of disease and a 
high level of CD8+ CTL activity. In an animal model experiment, the depletion of 
CD8+ lymphocytes during primary SIV infection resulted in a rapid and marked 
increase in viraemia, which was again suppressed with the presence of SIV-specific 
CD8+ T cells (Schmitz et al., 1999). These observations suggest the importance of 
CD8+ T cells in effective control of viremia and could form the basis of an HIV-1 
vaccine strategy. 
 
HIV-specific CD8+ T cells can function by direct killing of HIV infected cells or by 
secreting a number of antiviral factors. Unlike the neutralising antibodies that only 
target viral envelope proteins, the CD8+ CTLs may recognise a variety of HIV 
peptides, such as Gag, RT, Env and some accessory proteins (McMichael and 
Rowland-Jones, 2001). As the infection progresses, CD8+ T cell responses decline and 
fail to suppress viral load persistently. CTLs are believed to exert a selective force on 
HIV in vivo, giving rise to viruses that have mutated critical peptides and eventually 
escape CTL recognition (McMichael and Rowland-Jones, 2001).  This has been 
confirmed by several clinical studies where mutated epitopes have been observed to 
avoid CD8+ CTL responses (Phillips et al., 1991, Borrow et al., 1997, Price et al., 
1997). 
 
CD4+ T cell response almost appears at the same time of CD8+ T cell response (Pitcher 
et al., 1999). CD4+ T helper (TH) cells can be divided into TH1 and TH2 subsets, 
which both respond to HIV infection through production of cytokine (Mosmann et al., 
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1986). TH1 produces interleukin (IL)-2, interferon (IFN)-γ and tumour-necrosis factor 
(TNF)-α that can facilitate cell-mediated immunity; TH2 produces IL-4, 5, 6, 10 and 
13 that increase antibody production (humoral immunity). In addition, CD4+ T cells 
are important in the priming and maintenance of CD8+ T cells (Sun et al., 2004). Mice 
studies indicated that CD8+ T cell memory development was impaired with the 
depletion of CD4+ T cells (Shedlock and Shen, 2003, Sun and Bevan, 2003). However, 
since CD4+ T cells are the principal targets of HIV, the CD4+ T cell response is 
diminished at the early stage of infection and its contribution to the immune system is 
severely compromised. Vaccines that can elicit both CD4+ and CD8+ T cell responses 
to HIV may be beneficial to control viral infection at the early stage. 
 
 
1.1.8 The humoral responses of HIV infection 
 
Antibodies usually appear within one to two weeks after the acute infection. Generally 
IgG1 antibody dominates in all the clinical stages, while levels of other antibody 
classes can vary on different clinical stages (Barker et al., 1995). The early antibodies 
recognise Gag protein and are not neutralising (Busch et al., 1995). They induce 
antibody dependent cellular cytotoxicity (ADCC) against gp120 and gp41 (Evans et 
al., 1989), by which infected cells are recognised by effector NK cells or by 
monocytes/macrophages bearing fragment crystallisable (Fc) receptors and eventually 
destroyed (Yagita et al., 1992).  
 
Neutralising antibodies targeting Env normally appear after two to three months and 
their antiviral activities vary greatly between individuals (McKnight et al., 1992, Li et 
al., 2006). Most studies on neutralising antibodies indicated that a number of regions 
on gp120 and gp41 are sensitive to antibody neutralisation: the V3 loop, the V1, V2 
region and the CD4 binding domain of gp120, the membrane-proximal external region 
(MPER) of gp41 and the carbohydrate moieties covering viral envelope (figure 1.6) 
(Chanh et al., 1986, Muster et al., 1993, Trkola et al., 1996). While most of the 
identified neutralising antibodies recognise and neutralise a particular virus isolate, 
there are a few broadly neutralising monoclonal antibodies (mAb) that show cross-
clade neutralising activity against different viral strains (see below). 
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Figure 1.6 Broadly neutralising mAbs against HIV 
A variety of broadly neutralising mAbs have been identified, allowing targeting 
different epitopes on the surface of HIV. The figure illustrates the bilayer viral 
membrane, the viral envelope spike gp41 and gp120, and the glycans (dark blue and 
green). Broadly neutralising mAbs recognise at least four distinct epitopes on the 
envelope spike: b12, VRC01 and HJ16 target the CD4 binding sites on gp120; PG9 
and PG16 target the V1/V2 and V3 loop on gp120; 2G12 targets the outside glycans; 
2F5 and 4E10 target the MPER of gp41. The figure is adapted from (Burton and 
Weiss, 2010). 
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The characterised neutralising mAbs are described in detail below: 
 
b12 
The b12 antibody, isolated in early 1990s by Burton and his colleagues from a phage 
display library assembled from 5 ml of bone marrow cells of a LTNP donor, was the 
first identified and most extensively characterised broadly neutralising mAb against 
HIV-1 (Burton et al., 1991, Burton et al., 1994). Epitope mapping identified an epitope 
(RPVVSTQLLLNGSLAEEEVV) that overlaps the CD4 binding site of gp120 (Barbas 
et al., 1992). Therefore, the antibody could block HIV from attaching to CD4 receptor 
and thus prevent infection. Analysis of the b12 crystal structure in complex with gp120 
showed its binding to the outer domain surface of gp120 with high affinity without 
additional gp120 conformational constraints (Zhou et al., 2007). In comprehensive 
cross-clade neutralisation analysis b12 effectively neutralised 50% of 90 viruses 
crossing almost every subtypes, including primary isolates (Binley et al., 2004). In vivo 
studies also showed that b12 protected macaques from simian human 
immunodeficiency virus (SHIV) challenge (Parren et al., 2001). 
 
2G12 
The mAb 2G12 was produced from immortalised peripheral blood lymphocyte (PBL) 
by electrofusion (Buchacher et al., 1994). 2G12 recognises a complex mannose-
dependent epitope on the carbohydrate-covered silent face of the gp120 outer domain 
(Trkola et al., 1996, Sanders et al., 2002). 2G12 can neutralise HIV in subtype A, B 
and D, but not clade C nor CRF01_AE. This insensitivity of neutralising ability may be 
due to the absence of one or more glycans required for efficient 2G12 binding to gp120 
(Binley et al., 2004). In passive transfer studies 2G12 can protect macaques from viral 
infection, especially in combination with other broadly neutralising mAbs (Baba et al., 
2000, Mascola et al., 1999). The crystal structure of 2G12 indicates that the antibody 
can achieve nanomolar-binding affinity to a glycan array because of its unusual 
configuration of the antigen-binding fragments (Fabs) (Calarese et al., 2003). The 
variable heavy chains of the antibody have exchanged positions to interact with the 
light chain of the neighbouring Fab, resulting in a single, large antigen-binding site.  
 
2F5 and 4E10 
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The 2F5 and 4E10 mAbs were also isolated by Buchacher and his colleagues 
(Buchacher et al., 1994). These two broadly neutralising mAbs recognise two 
conserved linear epitopes (ELDKWAS and NWFDIT, respectively) on MPER of gp41. 
2F5 and 4E10 can bind to the envelope trimer at various stages of infection, and 
neutralisation may occur by interrupting gp41 refolding (Crooks et al., 2005). 4E10 
showed very broad neutralising activity across all HIV clades tested, with modest 
potency relative to b12 (Binley et al., 2004). However, 4E10 exhibits wide variation 
between different assay systems. 2F5 has a broad neutralising activity against clade A, 
B, D and CRF01_AE, but does not neutralise clade C viruses. Both 2F5 and 4E10 are 
unusual in having long complementarity-determining region 3 (CDR3) (22 and 18 
amino acids respectively) (Zwick et al., 2004, Cardoso et al., 2005), which are very 
rarely present in infected patients. Recent experiments have shown that both 2F5 and 
4E10 can protect macaques from mucosal challenge of SHIV (Hessell et al., 2010). 
 
PG9 and PG16 
Walker and his colleagues identified two antibodies PG9 and PG16 with exceptional 
neutralising breadth and potency through a large-scale direct functional screen of 
approximately 30,000 B cells (Walker et al., 2009). PG9 and PG16 were isolated from 
a clade A donor, and recognise an epitope encompassing V1/V2 and V3 variable loops 
on gp120. Interestingly, even though PG9 and PG16 efficiently neutralised more than 
70% of the 162 viruses including primary isolates, they didn’t bind to monomeric 
gp120 or gp41. This observation suggested that the epitopes targeted by these two 
antibodies might be preferentially expressed only on trimeric HIV envelope. A very 
long H-CDR3 loop of 28 residues was also defined on both antibodies and structural 
study revealed that the long CDR H3 loop forms a novel, sulphated “hammerhead” 
sub-domain that mediate potent neutralisation (Pejchal et al., 2010). 
 
HJ16 
A broadly neutralising mAb HJ16 was discovered by Corti and his colleagues (Corti et 
al., 2010). This antibody, isolated by improved Epstein-Barr Virus (EBV) 
immortalisation method (Traggiai et al., 2004), recognises a novel epitope proximal to 
the CD4 binding site on gp120. HJ16 showed reactivity that was comparable in 
breadth, but distinct from another CD4 binding site-specific neutralising mAb b12. In 
addition, unlike most antibodies that preferentially neutralise tier-1 isolates 
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(homologous vaccine strains that are very sensitive to neutralisation), HJ16 
preferentially neutralises tier-2 isolates (primary isolate Env clones) (Corti et al., 
2010). 
 
VRC01 and VRC02 
Wu and his colleagues successfully identified two broadly, potent neutralising mAbs 
VRC01 and VRC02 using a genetically engineered gp120. The newly designed gp120, 
showed no binding to most of non-neutralising antibodies, but preferentially bound to 
broadly neutralising antibodies (Wu et al., 2010). Targeting specifically to the 
conserved CD4 binding site, VRC01 and VRC02 neutralised about 90% of 190 viral 
strains represented all major circulating HIV-1 subtypes. Both antibodies exhibited 
high levels of somatic mutations. Detailed analysis of the antibody sequences revealed 
32% of variable region of heavy chain (VH) and 17% to 19% of variable region of 
kappa chain (Vκ) nucleotides had mutated from the putative germline sequences. More 
importantly, the isolation of VRC01 and VRC02 from an HIV-1 infected donor using a 
rationally designed Env has demonstrated that such neutralising antibodies were indeed 
elicited in human (table 1.1).  
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Table 1.1 
MAb Target epitopes Neutralising ability Special features 
b12 CD4-binding site Potently neutralise 50% of 90 
viruses across all subtypes 
Long CDR3 loop 
2G12 Complex mannose Neutralise subtype A, B and D VH domain swap 
2F5 Membrane proximal 
region of gp41 
Neutralise subtype A, B, D and 
CRF01_AE 
Long CDR3 
region 
4E10 Membrane proximal 
region of gp41 
Modestly neutralise 90 viruses 
across all subtypes 
Long CDR3 
region 
PG9 
PG16 
V1/V2 and V3 
domain 
Potently neutralise more than 
70% of 162 viruses across 
almost all subtypes 
Long, sulphated, 
“hammerhead” H-
CDR3 loop  
HJ16 Proximal to CD4 
binding site 
Neutralising ability comparable 
to, and generally complementary 
to b12; preferentially neutralise 
tier-2 isolates 
Preferentially 
neutralise tier-2 
isolates 
VRC01
VRC02 
Conserved CD4 
binding site 
Neutralise 91% of 190 viral 
strains represented all major 
circulating HIV-1 subtypes 
Highly mutated 
VH and Vκ 
 
Table 1.1 Broadly neutralising mAbs 
 
 
	   	   	  34	  
1.1.9 Long-term non-progressor (LTNP) 
 
Individuals who have been HIV positive for 7 to 15 years (different authors use 
different time spans) but not on ART and have not developed AIDS are defined as 
long-term non-progressors (LTNPs). LTNPs normally maintain stable CD4+ counts of 
500-600 cells/µl. A subset of LTNPs can even control their viral load to undetectable 
level and are named elite suppressors (ES). LTNPs have a number of characteristics 
that distinguish them from other HIV-1 infected individuals. A study of 68 LTNPs 
indicated that LTNPs maintain lower median plasma viral RNA than controls (6,000 vs. 
40,000 RNA copies/ml), but the levels can vary greatly between individuals (Candotti 
et al., 1999). Research showed that the CD4+ T cell-associated viruses were much 
lower in LTNPs. Moreover, a high level of anti-HIV-1 CD8+ memory CTL specific for 
viral protein Gag, Pol and Env was also associated with lack of AIDS progression in 
LTNPs, indicating that CD8+ memory CTL response may play an important role in 
controlling HIV replication and preventing disease development in LTNPs (Rinaldo et 
al., 1995, Greenough et al., 1999).  
 
Many studies defining the viral genetic characteristics of LTNP have focused on 
deletion of nef gene of HIV. A cohort of LTNPs (one blood donor and six blood 
transfusion recipients) was well studied (Deacon et al., 1995). HIV-1 sequences from 
their PBMCs had similar deletions of the nef gene. However, various results have been 
shown in subsequent studies, and nef deleted gene was only partially shown or absent 
in other LTNP studies (Greenough et al., 1999). What role the nef gene plays in LTNP 
is not known. 
 
Meanwhile, studies on human genetic variability that may affect HIV susceptibility 
have been focusing on CCR5 receptor. Several studies showed that a deletion of 32 
base pairs in the CCR5 gene might be responsible to the resistance of HIV infection. 
The truncated protein cannot be detected by virus at the cell surface (Liu et al., 1996). 
However, others showed that CCR5 might not be the only reason for the lack of 
disease in LTNP (Cohen et al., 1997, Morawetz et al., 1997). No differences of 
immunological and virologic parameters were found between LTNPs with deleted 
CCR5 and those with wild-type CCR5, thus indicating other factors are involved. 
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Although the factor which determines the HIV infection and disease progression in 
LTNPs remains unknown, LTNPs have become an important subject in HIV and AIDS 
research. Many studies on HIV pathogenesis, immunogenesis and vaccine design are 
based on this cohort of individuals. In this study, samples from more than 300 HIV-1 
positive patients have been screened at Barts and The London Hospital, Queen Mary, 
University of London. Two serum samples from LTNPs M325 and K530 were found 
to have the wild type CCR5 and they displayed cross-clade neutralising activity (Weiss 
et al., 1986) at high titres (see appendix 1), suggesting neutralising antibodies might 
have been generated by the two patients. 
 
 
1.1.10 Ribosome display 
 
It has been shown that broadly neutralising mAbs can be isolated by phage display 
(Burton et al., 1991), electrofusion or EBV transformation (Buchacher et al., 1994). 
Recently, a high-throughput functional screening approach has been used to isolate 
potent neutralising mAbs from B cell culture (Walker et al., 2009).  
 
In this study, ribosome display technology was investigated for in vitro antibody 
discovery from libraries made from HIV-1 LTNPs. Ribosome display is a cell-free 
system, in which DNA library can be rapidly screened without the need for cloning 
(He and Taussig, 1997). Like all other display technologies, ribosome display uses the 
same principle of linking proteins (phenotype) and DNA (genotype) for selection. 
Ribosome display produces stable Antibody-Ribosome-mRNA (ARM) complexes to 
link individual antibody fragments to their corresponding mRNA (He and Taussig, 
2002). The formation of ARM complexes is achieved through deletion of the stop 
codon from the mRNA, which causes stalling of the translating ribosome at the end of 
mRNA with the nascent polypeptide not released. The linkage of protein-mRNA 
allows simultaneous selection of desirable antibodies with their encoding mRNA 
which can be recovered and amplified as DNA by RT-PCR (He et al., 2004). Through 
repeated cycles, specific antibodies originally presented in rare species can be enriched 
and isolated from a very large population. Ribosome display enables screening 
libraries with up to 1012-13 members in a single reaction.  
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1.1.11 E. coli expression of proteins 
 
Expression systems for producing recombinant protein (e.g. antibody) include those 
derived from bacteria (Baneyx, 1999), yeast (Cregg et al., 2000), Baculovirus (Kost et 
al., 2005) and mammalian cells (Rosser et al., 2005). Among these, Escherichia coli 
(E. coli) is widely used for expression of recombinant proteins due to its relative 
simplicity, low cost, easy cultivation, the well-studied genetics and the availability of 
compatible tools (Sorensen and Mortensen, 2005). Moreover, varieties of plasmids and 
bacterial hosts including mutant strains are available, making it possible to express 
protein under a condition of choice. Although expression of soluble proteins in E coli 
is still a bottleneck, a couple of empirical rules have been developed to guide the 
design and selection of an expression system (Makrides, 1996).  
 
Recombinant expression plasmids contain a promoter to control protein synthesis; it 
should also exhibit a minimal level of basal transcriptional activity. The minimal basal 
transcription is controlled by a suitable suppressor, which in most cases is lac 
repressor, encoded by lacI gene or its mutants. Most widely used promoters can be 
induced by using either a thermal method or chemical inducers, e.g. Isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside (IPTG) (Hannig and Makrides, 1998). In this study, pSANG 
vector, adapted from pET26(+) vector (Novagen, Nottingham, UK), utilises a T7/lac 
hybrid promoter which combines the strong T7 promoter with the lac operator (figure 
1.7). Basal expression of the protein is controlled by the lac repressor, encoded by the 
lacI gene. The T7 promoter requires the presence of the T7 RNA polymerase in the 
expression system, such as BL21(DE3) strain (Martin et al., 2006). Another vector 
(pABEXT) used in this study was modified from pMAL-c2X vector (New England 
Biolabs, Hitchin, Herts, UK). pABEXT vector contains the tac promoter, which is also 
controlled by the lac repressor, encoded by the lacIq gene (figure 1.8). The tac 
promoter is not as strong as T7 promoter, but it allows expression in E. coli without the 
need for T7 RNA polymerase.  
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Figure 1.7 Schematic view of the expression cassettes of the pSANG10-3F vector 
The single-chain antibody encoding genes are sub-cloned at the NcoI/NotI sites. 
Picture is adapted from (Martin et al., 2006). 
 
 
 
 
Figure 1.8 Schematic view of the expression cassettes of the pABEXT vector 
pABEXT vector is constructed using pMAL-c2X vector as backbone. The single-chain 
antibody encoding genes are sub-cloned at the NcoI/NotI sites.  
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Apart from the expression vector, the choice of a strain and its genetic background also 
affects protein expression. Some key features for an expression strain have been 
identified. These include deficiency in the most harmful proteases, maintenance of 
expression plasmid stability and the genetic elements relevant to the expression system 
(e.g., DE3) (Sorensen and Mortensen, 2005). E. coli BL21 is a robust host strain and 
has been used widely in recombinant expression applications. BL21 is deficient in two 
proteases, OmpT and Lon, reducing the possibility of protein degradation and thus 
allowing isolation of intact recombinant proteins. BL21(DE3) is the preferred host for 
vectors containing T7 promoter , as it encodes the T7 RNA polymerase gene under the 
control of lacUV5 promoter. To eliminate the rare codon bias in E. coli expression, 
BL21(DE3) strain was further modified to introduce a plasmid pRARE encoding some 
rare transfer RNAs (tRNAs) to overcome the shortage of the rare tRNA pools from 
bacteria (Novy et al., 2001). In this study, the DNA ligation with pSANG vector was 
firstly used to transform XL1-blue strain due to its high transformation efficiency and 
blue/white screening; positive clones were subsequently transformed into 
BL21(DE3)pRARE strain for protein expression. Antibodies that are used in functional 
assays were produced by this method. An alternative strategy was also attempted in 
this study, in which the DNA ligation with pABEXT vector was transformed into XL1-
blue strain for both cloning and expression without the second transformation step. 
This strategy was performed for a quick screening purpose. Figure 1.9 illustrates the 
two different approaches for expression of proteins in E. coli.  
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Figure 1.9 Two strategies of antibody expression 
Two strategies were used in this study to express antibodies selected by ribosome 
display: (1) antibodies were cloned into pSANG vector and expressed in 
BL21(DE3)pRARE cells as illustrated to the left of the figure; (2) antibodies were 
cloned into pABEXT vector and expressed in XL1-blue cells as illustrated to the right 
of the figure.  
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The way to express proteins also affects protein yields. The expression strategies in 
general include synthesis of the proteins in (1) the reducing environment of the 
cytoplasm; (2) the oxidising environment of the periplasmic space, which is located 
between the cytoplasm and outer membranes, or (3) direct secretion of the protein into 
the culture medium (Gualerzi and Pon, 1990). The cytoplasmic expression approach 
benefits from a high expression level through a strong promoter, but most proteins 
produced form insoluble aggregates as inclusion bodies (Makrides, 1996). The 
advantages of recovering recombinant proteins from inclusion bodies are high yield 
(Zhuo et al., 2005), protection from proteases (Grune et al., 2004) and permitting 
production of proteins that are lethal to the host cells (Miroux and Walker, 1996). 
However, a tedious refolding process is needed to regain soluble active protein. Since 
refolded proteins often do not reproduce their original biological activities, efforts have 
been directed to avoid or minimise the formation of inclusion bodies (Schein, 1991). 
Secretion of proteins into periplasmic space (periplasmic expression) or extracellular 
medium (extracellular secretion) provides an alternative to facilitate correctly folded 
proteins. They are achieved by using a leader sequence, such as OmpT, OmpA, PelB 
and MalE (Blight et al., 1994). Compared with cytoplasmic expression, this strategy 
allows simpler purification, protection of proteins from proteolysis, generation of 
higher N-terminus authenticity and enhancement of disulfide bond formation (Jonasson 
et al., 2002).  
 
Another factor affecting efficient protein expression in E. coli is the codon usage. 
Certain codons are rare in E. coli while abundant in heterologous genes from sources 
such as eukaryotes (Kane, 1995, Rosano and Ceccarelli, 2009). Expression of genes 
with rare codon in E. coli may lead to translational errors and severely impair the 
translation efficiency. The most problematic codons include Arginine (AGA, AGG, 
CGA and CGG), Glycine (GGA and GGG), Isoleucine (AUA), Leucine (CUA) and 
Proline (CCC) (Sorensen and Mortensen, 2005). Approaches to decrease codon bias 
include site-directed mutagenesis of the target sequence (Calderone et al., 1996) and 
complement of gene encoding the tRNA cognate to the problematic codons (Dieci et 
al., 2000). Assembly of rare tRNA genes into plasmid such as pRIG and pRARE in the 
host strain has shown to be able to significantly enhance the expression of some codon 
biased genes (Baca and Hol, 2000).  
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1.1.12 HIV-1 Antibody neutralisation assay 
 
The anti-HIV-1 antibody activity resulting in the prevention of virus entry into cells is 
an important functional attribute. This may be achieved by binding to the viral surface 
protein envelope, preventing virus attachment and/or entry into cells (Wyatt and 
Sodroski, 1998). Neutralisation epitopes for HIV-1 include the CD4 binding domain 
(Burton et al., 1991), the hypervariable regions (V1, V2 and V3) of gp120 (Haigwood 
et al., 1990, Fung et al., 1992, Gorny et al., 1991, Pinter et al., 1993), the MPER of 
gp41 (Buchacher et al., 1994, Stiegler et al., 2001) and the mannose residues on the 
outer face of gp120 (Trkola et al., 1996, Scanlan et al., 2002).  
 
The HIV-1 neutralisation assay is designed to analyse the activity of neutralising 
antibodies. Many parameters may affect this neutralisation assay, and thus a 
standardised in vitro assay is important for meaningful comparisons of the quality and 
potency of neutralising antibodies. Early studies on HIV-1 neutralising antibody 
responses relied on the ability of T-cell line adapted (TCLA) viruses to infect cell lines. 
Sera or recombinant antibodies were used to co-culture with TCLA virus, and 
parameters such as syncytium-formation, viral proteins or cell survival were measured 
to evaluate reduction of infection (Nara et al., 1987, Hanson et al., 1990, Montefiori et 
al., 1988). However, neutralisation of TCLA viruses poorly predicted primary isolate 
neutralisation because the adapted primary viruses in T-cell lines are highly sensitive 
to neutralisation (Wrin et al., 1995). To mimic the in vivo environment, assays using 
patient viruses to infect seronegative PBMCs were subsequently developed. Primary 
viruses or clinical isolates were co-cultured with the test sera or mAbs, and viral 
protein or reverse transcription was measured to indicate viral replication (Mascola, 
1999, Mascola et al., 2002). However, these assays require the use of PBMCs from 
different individuals, which display differential susceptibility to HIV-1 infection and 
impair the experiment reproducibility (Daar et al., 1990, Zhou and Montefiori, 1997). 
 
Recently, a technology that uses pseudovirus in a neutralisation assay (Richman et al., 
2003) was adapted and refined by Montefiori. The pseudoviruses are generated by 
incorporating HIV-1 Env cloned from primary isolates into Env-deficient laboratory-
adapted strains, which were only capable of a single round of infection (Montefiori, 
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2005). The neutralising activity of test sera or antibodies is measured by reduction of 
infectivity on reporter cell lines, such as TZM-bl that contains the β-galactosidase and 
luciferase as sensitive markers (Wei et al., 2002). Compared to the PBMC assay, the 
pseudoviral system has advantages on the ability to produce generically identical virus 
in each stock, and rapid test for neutralisation against primary patient Envs from 
various clades (Polonis et al., 2008). In general, this system greatly enhanced the 
consistency, accuracy and reproducibility of the neutralisation assay. Despite the 
discrepancies reported between reporter cell line-based pseudovirus assays and PBMC-
based assays (Binley et al., 2004), the pseudovirus assay has been recommended by the 
HIV Vaccine Trials Network (HVTN) and National Institutes of Health (NIH) as the 
standard assay for evaluating neutralising antibody responses (Mascola et al., 2005). 
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1.2 Aims of the project 
 
 
Despite of three decades of intensive research, an effective vaccine for the prevention 
of HIV infection has proved to be elusive. Significant efforts have been made in 
understanding the molecular biology of the HIV vaccines, in particular the role of viral 
encoded protease and reverse transcriptase. Moreover, an understanding of the 
molecular functions that allow viral whole cell recognition and cell entry has also 
being elucidated. With the detailed knowledge of the protease and the reverse 
transcriptase, considerable success has been achieved in developing drugs to target 
these molecules for the disruption of virus propagation.  
 
The current approach for the treatment of the HIV positive individuals relies on a 
cocktail of these drugs. However, ideally what is required is a vaccine that may prevent 
the initial infection, or hold an infection in check. With the detailed understanding of 
the viral surface molecular architecture, molecules responsible for the attachment to 
the cell surfaces and viral entry have been identified. It may be possible to target some 
of these surface molecules to prevent either initial attachment or subsequent entry into 
the whole cell, such as gp120. However, since it is heavily glycosylated, the peptide 
sequences are possibly hidden from the immune surveillance molecules. 
Notwithstanding, it was shown that immune sera from HIV-1 LTNPs are capable of 
neutralising a broad range of HIV isolates. To date, a number of broadly neutralising 
human mAbs have been isolated. Analysis of these antibodies by epitope mapping 
facilitates to identify the amino acid sequences capable of inducing broadly protective 
HIV antibodies. Studies on such many different neutralising antibodies would help us 
to understand both the molecular mechanism and the nature of the broadly neutralising 
responses. It is clear that methods are needed to rapidly select many different 
neutralising antibodies for analysis and characterisation. 
 
This study aimed to establish an approach to identify neutralising mAbs in vitro using 
cell-free ribosome display from cDNA libraries made from patient PBMCs, combined 
with homologous and heterologous gp120 selection. Secondly, the relationship 
between binding, neutralising activity and the antibody subclasses was also 
determined. The donors (M325 and K530) had previously been identified as LTNPs 
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with broadly neutralising activity against clade B, C, CRF02_AG. The hypothesis was 
to investigate the antibody repertoire to determine whether similar antibody solutions 
were used in this common broad neutralisation activity. It was reasoned that donor 
M325 should have antibodies directed against gp120 derived from K530. 
 
The followings are the main steps involved in this project: 
(1) Construction of ribosome display libraries from two HIV-1 LTNPs; 
(2) Carrying out ribosome display to select antibodies against antigen gp120; 
(3) E. coli cloning and expression of selected population as single-chain variable 
fragment (scFv); 
(4) ELISA screening for potential gp120 binders; 
(5) Analysis and characterisation of binders. 
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Chapter 2  
 
Materials and Methods 
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2.1 Materials  
 
 
2.1.1 Molecular biology reagents/kits 
 
MP biomedicals, Illkirch, France 
Taq & Go Ready to Use PCR Mix 
 
New England Biolabs, Hitchin, Herts, UK 
10X NEBuffer 3, 10X T4 DNA ligase reaction buffer, 100 base pair (bp) DNA ladder, 
Protoscript	   ® First Strand cDNA Synthesis Kit, restriction Endonucleases HindIII, 
NcoI, NdeI, NotI, T4 DNA ligase  
 
Promega, Southampton, Hampshire, UK 
Bright-GLo Luciferase reagent, TNT® T7 Quick Coupled Transcription/Translation 
System  
 
Qiagen, Crawley, West Sussex, UK 
Ni-NTA Spin Columns, QIAquick Gel Extraction Kit, QIAprep Spin Miniprep Kit, 
QIAexpress Kit  
 
Roche Diagnostics Ltd., Burgess Hill, West Sussex, UK 
DNase I recombinant  
 
Sigma-Aldrich, Poole, Dorset, UK 
Amicon Centrifugal Filter Units  
 
Thermo Fisher Scientific, Loughborough, Leicestershire, UK 
SuperScript® III One-Step RT-PCR System with Platinum® Taq DNA Polymerase, 
TOPO TA Cloning® Kit for Sequencing, TRIZOL® Reagent  
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2.1.2 Chemicals 
 
Becton, Dickinson and Company, Oxford, UK 
Bactotryptone, Yeast extract  
 
BIO-RAD Laboratories Ltd., Hemel Hempstead, Hertfordshire, UK 
Precision plus protein dual Xtra standards  
 
GBIOSCIENCES, Maryland Heights, MO 63043-3202, U.S.A. 
Nickel chelating resin  
 
Merck, Darmstadt, Germany 
5-bromo-4-chloro-3-indolyl phosphate (BCIP), Nitro blue tetrazolium (NBT)  
 
Sigma-Aldrich, Poole, Dorset, UK 
Agarose, β-mercaptoethanol, dithiothreitol, Diethylaminoethyl (DEAE)-dextran, Mg 
acetate, Monoclonal anti-polyHistidine-alkaline phosphatase antibody produced in 
mouse  
 
Thermo Fisher Scientific, Loughborough, Leicestershire, UK 
0.2 ml PCR tube, 50 ml centrifuge tube, 5-bromo-4-chloro-3-indolyl-beta-D-
galactopyranoside (X-gal), 96 well flat bottom opaque Nunc plate, acetic acid glacial, 
acrylamide: bis-acrylamide 29:1 solution 40%, ammonium persulfate, Bovine serum 
albumin (BSA), Bromophenol blue, CaCl2, carbenicillin, chloramphenicol, Coomassie 
brilliant blue R-250, Diethylpyrocarbonate (DEPC)-treated H2O, Dulbecco's modified 
Eagle medium (DMEM), F96 MaxiSorp Nunc-Immuno plate, glucose, glycerol, 
Glycine, guanidine hydrochloride, guanidine thiocyanate, imidazole, Immobilon-P 
transfer membrane, Isopropyl β-D-1-thiogalactopyranoside  (IPTG), isopropyl alcohol, 
kanamycin, KCl, Luria Bertani (LB) agar, LB broth, methanol, MgCl2, MgSO4, NaCl, 
p-Nitrophenyl phosphate (pNPP), Sodium dodecyl sulphate (SDS), tetracycline, 
Tetramethylethylenediamine (TEMED), Tris base, Tween 20  
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2.1.3 Equipments 
 
BIO-RAD Laboratories Ltd., Hemel Hempstead, Hertfordshire, UK 
Mini-PROTEAN Tetra Electrophoresis System, Mini Trans-Blot Cell  
 
BMG Labtech, Aylesbury, UK 
FLUOstar OPTIMA  
 
Clare Chemical Research, Dolores, USA 
Dark Reader Transilluminator DR-88X  
 
Thermo Fisher Scientific, Loughborough, Leicestershire, UK 
Nanodrop 1000 Spectrophotometer  
 
Wallac, PerkinElmer, Cambridge, UK 
VICTOR Plate Reader  
 
 
2.1.4 Oligonucleotide primers 
 
All the oligonucleotide primers used for antibody library construction, ribosome 
display and scFv expression are listed in the table 2.1. Primers/oligonucleotides were 
synthesised from Invitrogen (Paisley, UK). 
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Table 2.1 
First strand cDNA and variable fragments (reverse) 
HuKF TCC AGA TTT CAA CTG CTC ATC AGA TGG CGG 
HuLF GGC TTG GAG CTC CTC AGA GGA GGG YGG GAA 
CH2F GGG TRT CCT TGG GTT TTG GGG GGA A 
Variable kappa (Vκ) (forward) 
VK1 GAC ATC CRG DTG ACC CAG TCT CC 
VK2346 GAT ATT GTG MTG ACB CAG WCT CC 
VK36 GAA ATT GTR WTG ACR CAG TCT CC 
VK5 GAA ACG ACA CTC ACG CAG TCT C 
Variable lambda (Vλ) (forward) 
VL1 CAG TCT GTS BTG ACG CAG CCG CC 
VL1459 CAG CCT GTG CTG ACT CAR YC 
VL15910 CAG CCW GKG CTG ACT CAG CCM CC 
VL2 CAG TCT GYY CTG AYT CAG CCT 
VL3A TCC TAT GWG CTG ACW CAG CCA C 
VL3B TCC TAT GAG CTG AYR CAG CYA CC 
VL3DLP16 TCC TCT GAG CTG AST CAG GAS CC 
VL6 AAT TTT ATG CTG ACT CAG CCC C 
VL78 CAG DCT GTG GTG ACY CAG GAG CC 
Variable heavy (VH) (forward) 
VH1 CAG GTC CAG CTK GTR CAG TCT GG 
VH1257 CAG GTG CAG CTG GTG SAR TCT GG 
VH2 CAG RTC ACC TTG AAG GAG TCT G 
VH3A GAG GTG CAG CTG KTG GAG WCC 
VH3B GAG GTG CAG CTG KTG GAG WCT 
VH4 CAG GTG CAG CTG CAG GAG TCS G 
VH4DP63 CAG GTG CAG CTA CAG CAG TGG  
VH6 CAG GTA CAG CTG CAG CAG TCA 
T7-variable kappa (T7 Vκ) (forward) 
VK1T7 CTA TAG GAA CAG ACC ACC ATG GCC GAC ATC CRG DTG ACC CAG TCT CC 
VK2346T7 CTA TAG GAA CAG ACC ACC ATG GCC GAT ATT GTG MTG ACB CAG WCT CC 
VK36T7 CTA TAG GAA CAG ACC ACC ATG GCC GAA ATT GTR WTG ACR CAG TCT CC 
VK5T7 CTA TAG GAA CAG ACC ACC ATG GCC GAA ACG ACA CTC ACG CAG TCT C 
T7-variable lambda (T7 Vλ) (forward) 
VL1T7 CTA TAG GAA CAG ACC ACC ATG GCC CAG TCT GTS BTG ACG CAG CCG CC 
VL1459T7 CTA TAG GAA CAG ACC ACC ATG GCC CAG CCT GTG CTG ACT CAR YC 
VL15910T7 CTA TAG GAA CAG ACC ACC ATG GCC CAG CCW GKG CTG ACT CAG CCM CC 
VL2T7 CTA TAG GAA CAG ACC ACC ATG GCC CAG TCT GYY CTG AYT CAG CCT 
VL3AT7 CTA TAG GAA CAG ACC ACC ATG GCC TCC TAT GWG CTG ACW CAG CCA C 
VL3BT7 CTA TAG GAA CAG ACC ACC ATG GCC TCC TAT GAG CTG AYR CAG CYA CC 
VL3DLP16T7 CTA TAG GAA CAG ACC ACC ATG GCC TCC TCT GAG CTG AST CAG GAS CC 
VL6T7 CTA TAG GAA CAG ACC ACC ATG GCC AAT TTT ATG CTG ACT CAG CCC C 
VL78T7 CTA TAG GAA CAG ACC ACC ATG GCC CAG DCT GTG GTG ACY CAG GAG CC 
Kappa link-heavy (κ link VH) (forward) 
VH1K CCG CCA TCT GAT GAG CAG TTG AAA TCT GGA CAG GTC CAG CTK GTR 
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CAG TCT GG  
VH1257K CCG CCA TCT GAT GAG CAG TTG AAA TCT GGA CAG GTG CAG CTG GTG SAR TCT GG  
VH2K CCG CCA TCT GAT GAG CAG TTG AAA TCT GGA CAG RTC ACC TTG AAG GAG TCT G 
VH3AK CCG CCA TCT GAT GAG CAG TTG AAA TCT GGA GAG GTG CAG CTG KTG GAG WCC 
VH3BK CCG CCA TCT GAT GAG CAG TTG AAA TCT GGA GAG GTG CAG CTG KTG GAG WCT 
VH4K CCG CCA TCT GAT GAG CAG TTG AAA TCT GGA CAG GTG CAG CTG CAG GAG TCS G 
VH4DP63K CCG CCA TCT GAT GAG CAG TTG AAA TCT GGA CAG GTG CAG CTA CAG CAG TGG G 
VH6K CCG CCA TCT GAT GAG CAG TTG AAA TCT GGA CAG GTA CAG CTG CAG CAG TCA 
Lambda link-heavy (λ link VH) (forward) 
VH1L CCC TCC TCT GAG GAG CTC CAA GCC CAG GTC CAG CTK GTR CAG TCT GG 
VH1257L CCC TCC TCT GAG GAG CTC CAA GCC CAG GTG CAG CTG GTG SAR TCT GG 
VH2L CCC TCC TCT GAG GAG CTC CAA GCC CAG RTC ACC TTG AAG GAG TCT G 
VH3AL CCC TCC TCT GAG GAG CTC CAA GCC GAG GTG CAG CTG KTG GAG WCC 
VH3BL CCC TCC TCT GAG GAG CTC CAA GCC GAG GTG CAG CTG KTG GAG WCT 
VH4L CCC TCC TCT GAG GAG CTC CAA GCC CAG GTG CAG CTG CAG GAG TCS G 
VH4DP63L CCC TCC TCT GAG GAG CTC CAA GCC CAG GTG CAG CTA CAG CAG TGG G 
VH6L CCC TCC TCT GAG GAG CTC CAA GCC CAG GTA CAG CTG CAG CAG TCA  
Combination (T7AB is forward, CH2Not is reverse) 
T7AB GCA GCT AAT ACG ACT CAC TAT AGG AAC AGA CCA CCA TGG CC 
CH2Not CCG GGA TGC GGC CGC GGT RTC CTT GGG TTT TGG GGG GAA 
Ribosome display (EP1, IP1 and LP1 are reverse, Kz1 is used on both directions) 
EP1 GCT ACC GCC TCC ACT CCC ACC GCC AGA TCC CCC ACC CGA GCC TCC CCC TGA ACC GCC TCC CCG GGA TGC GGC CGC RGT RTC CTT GG 
IP1 GAA CAG ACC ACC ATG AG GAA GAC TGA YGG TCC 
Kz1 GAA CAG ACC ACC ATG 
LP1 
GCTGCT ACC GCC TCC ACT CCC ACC GCC AGA TCC CCC ACC CGA GCC TCC 
CCC TGA ACC GCC TCC CCG GGA TGC GGC CGC GAA CAG ACC ACC ATG AG 
GAA GAC 
scFv expression (reverse) 
TJ011 GCC CGC GGC CGC TGT GCC CCC AGA GGT G 
TJIgG24 GCC CGC GGC CGC TGT GCT CTC GGA GGT G 
 
Table 2.1 Primers used in PCR 
Primers Degenerate codons used for synthesising variable regions are: M=A/C; 
R=A/G; W=A/T; S=G/C; Y=C/T; K=G/T; V=A/G/C; H=A/C/T; D=A/G/T; B=G/C/T; 
N=A/G/C/T. Primer directions are shown in brackets. 
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2.1.5 Plasmids 
 
Protein expression vector pSANG10-3F (Martin et al., 2006) was provided by Dr. John 
McCafferty (Department of Biochemistry, University of Cambridge). Plasmid pMal-
c2X (used to construct vector pABEXT) was purchased from New England Biolabs 
(Hitchin, Herts, UK).   
 
 
2.1.6 Cell culture 
 
E. coli strain XL1-blue [recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac (F´ 
proAB lacIqZΔM15 Tn10 Tetr)] competent cells used for plasmid transformation were 
purchased from Stratagene (California, USA). E. coli strain BL21(DE3)pRARE 
competent cells used for protein expression were made from E. coli BL21(DE3) [F– 
dcm ompT hsdS(rB– mB–) gal λ(DE3)] (Merck, Nottingham, UK) with plasmid pRARE 
in Dr. Angray Kang’s lab (School of Life Sciences, University of Westminster, UK).  
 
PBMCs from two HIV-1 patients (M325 and K530) were kindly provided by Dr. 
Hanna Dreja (Centre for Infectious Disease, Institute of Cell and Molecular Science, 
Barts and The London, Queen Mary, University of London, UK). Serum neutralising 
activities of these two patients were tested by Dr. Hanna Dreja and are listed in the 
appendix 1.  
 
Recombinant antigen gp120 generated from HIV-1 virus isolated from patient K530’s 
serum was provided by Dr. Simon A. Jeffs (Wright-Fleming Institute, Division of 
Medicine, Imperial College London, UK). This was selected because it was 
homologous for use in screening the K530 library and heterologous for the M325 
library. 
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2.2 Construction of human single-chain antibody libraries 
 
From each of the two individual patient PBMCs (M325 and K530), a human single-
chain antibody library was constructed respectively, and designated M325 and K530. 
First, total RNA was extracted from the corresponding patient PBMCs. The RNA was 
then used to synthesis first strand complementary DNA (cDNA) using specific primers 
followed by PCR using designed primers to amplify the variable regions. Finally 
single-chain antibody libraries were constructed by assembling all individual variable 
regions of light chains (VLs) with individual heavy chains (VH-CH1-hinge-partial 
CH2) by PCR. Detailed procedures are described below.  
 
 
2.2.1 Total RNA extraction 
 
PBMCs from patient M325 were isolated from 100 ml of the whole blood using Ficoll 
gradient centrifugation prior to the treatment with 5 ml of TRIZOL® Reagent for 
homogenisation, while PBMCs from patient K530 were recovered from 20 ml of the 
whole blood by the same way and the isolated PBMCs had been stored at -80°C for 3 
years before use.  To extract total RNA from the PBMCs K530, 2 ml of TRIZOL® 
Reagent was added to disrupt cells and dissolve cell components, as well as eliminate 
the potential hazards of HIV-1 infection.  
 
Total RNA was isolated using TRIZOL® Reagent according to the manufacture’s 
instruction. In brief, 0.2 ml of chloroform was added per 1 ml of TRIZOL® Reagent 
used for the initial homogenisation, and the sample was shaken vigorously for 15 
seconds and incubated at room temperature for 15 minutes. The sample was then 
centrifuged at 12000 g for 15 minutes at 4°C, and the upper aqueous phase was 
transferred to a fresh tube. RNA was precipitated from the aqueous phase by adding 
0.5 ml of isopropyl alcohol for every 1 ml of TRIZOL® Reagent. After incubation at 
room temperature for 10 minutes, the mixture was centrifuged at 12000 g for 10 
minutes at 4°C. The supernatant was carefully removed, and the RNA pellet was 
washed with 1 ml of 75% ethanol per 1 ml of TRIZOL® Reagent, and centrifuged at 
7500 g for 5 minutes at 4°C. The RNA was dried in air for 10 minutes, before re-
dissolved by addition of 30 µl of DEPC-treated H2O and stored at -80°C. 
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2.2.2 First strand cDNA synthesis 
 
Three first strand cDNAs (Vκ, Vλ and heavy chain) were synthesised from total RNA 
using Protoscript	  ® First Strand cDNA Synthesis Kit with specific primers (HuKF, 
HuLF and CH2F, respectively), according to the manufacturer’s instructions. Briefly, 1 
µg of total RNA was incubated at 70°C for 5 minutes with 30 pmol of primer, 40 nmol 
of dNTP mix and sufficient DEPC-treated H2O to a final volume of 16 µl. The mixture 
was cooled down on ice for at least 30 seconds before adding 2 µl of M-MuLV 
Reverse Transcriptase Reaction Buffer (10X RT Buffer), 1 µl of M-MuLV Reverse 
Transcriptase  (25 units) and 1 µl of RNase inhibitor (10 units). The mixture was 
incubated at 42°C for 1 hour, followed by 95°C for 5 minutes to inactivate the 
enzymes. 1 µl of RNase H (2 units) was then added to the mixture for 20 minutes at 
37°C to degrade the remaining RNA. Finally the mixture was incubated at 95°C for 5 
minutes to inactivate the enzyme. Synthesised first strand cDNAs were used to 
construct individual Vκ, Vλ and heavy chain fragments, respectively. 
  
 
2.2.3 Single-chain antibody library construction 
 
Individual fragments including 4 Vκ, 9 Vλ, and 8 heavy chains (VH-CH1-hinge-partial 
CH2) were amplified by PCR (figure 2.1). 5’-primers specific for individual Vκ, Vλ 
and VH families were designed to amplify all the functional variable regions of 
Immunoglobulin (Ig) G family (Sblattero and Bradbury, 1998). In order to identify the 
subclasses of neutralising mAbs, 3’-primers for heavy chains were designed to anneal 
at the beginning region of CH2 domain, thus amplifying VH-hinge-CH1 and partial 
CH2 which provides the information of immunoglobulin subclasses (IgG1, 2, 3 or 4). 
A secondary PCR was performed to introduce restriction endonuclease sites NcoI at 
the 5’ end of the VL (Vλ and Vκ) and NotI at the 3’ end of the CH2 for the cloning 
purpose, as well as a synthetic linker to join VL to heavy chain. Individual VL was 
linked with individual heavy chain through PCR to form Vκ-link-VH-CH1-hinge-
partial CH2 and Vλ-link-VH-CH1-hinge-partial CH2. In this way, a total of 104 
combinations of light chain and heavy chain families were generated (Figure 2.2).  
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Figure 2.1 Illustration of single-chain antibody library construction 
(1) Individual fragment (4 Vκ, 9 Vλ and 8 heavy chains) were generated by PCR; (2) 
each fragment was introduced restriction endonuclease sites and a linker sequence by 
PCR; (3) each light chain and heavy chain was assembled to each other, forming the 
single-chain antibody library. 
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Figure 2.2 Illustration of combinations of light chains and heavy chains 
In both libraries, individual light chain families and heavy chain families were 
randomly combined one by one by PCR assembly. 104 combinations were mixed for 
the use of ribosome display. 
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Taq & Go Ready to Use PCR Mix was employed in all PCR amplification. The 
following is the standard reaction mixture: 10 µl of 5X Taq & Go Ready to Use PCR 
Mix, 25 pmol of each primer, 2 µl of template and sufficient DEPC-treated H2O to a 
final volume of 50 µl. PCR was carried out using the condition of one cycle at 94°C 
for 5 minutes, followed by 30 cycles of denaturation at 94°C for 30 seconds, annealing 
at 50-60°C (depending on the primer pairs) for 30 seconds and extension at 72°C for 1 
minute, and one cycle of final extension at 72°C for 10 minutes.  
 
20 µl of PCR products were analysed by gel electrophoresis with 1.5% (w/v) agarose. 
DNA fragment size was determined by comparison with 100 bp DNA ladder. For 
purifying DNA from agarose gels, the piece of gel containing the desired DNA 
fragment was excised under Dark Reader Transilluminator DR-88X to eliminate 
ultraviolet (UV) damage and the DNA was extracted from the gel using QIAquick Gel 
Extraction Kit according to the manufacturer’s instructions. Briefly, excised agarose 
gel was dissolved in 300 µl of QG buffer (5.5 M guanidine thiocyanate, 20 mM Tris-
HCl, pH 6.6) and incubated at 50°C for 10 minutes. The solution was mixed with 100 
µl of isopropyl ethanol before loaded to QIAquick spin column and centrifuged at 
13000 g for 1 minute. The column was washed with 750 µl of PE buffer (20 mM NaCl, 
2 mM Tris-HCl, 80% ethanol, pH 7.5) and centrifuged at 13000 g for 1 minute. DNA 
was eluted in 30 µl of DEPC-treated H2O and stored at -20°C. 
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2.3 Ribosome display 
 
Both single-chain antibody libraries were screened by in vitro ribosome display 
according to protocol described (He and Taussig, 2007) with slight modifications. The 
steps of ribosome display cycle are illustrated in figure 2.3.  
 
 
2.3.1 Full-length generation of ribosome display construct  
 
To display antibodies on the surface of ribosome, the 5’ end of the library should 
contain T7 promoter and a eukaryotic translation initiation (Kozak) sequence (Kozak, 
1987). This was achieved by designing a T7AB primer (5’- GC AGC TAA TAC GAC 
TCA CTA TAG GAA CAG ACC ACC ATG GCC -3’). On the other hand, to 
efficiently recover the cDNA from ribosome complexes after selection without prior 
mRNA isolation, a primer annealing at the position about 60-80 bp upstream of the 3’ 
end is required as ribosome occupies about 60 nucleotides at the 3’ end. This would 
lead to the generation of cDNA short of 60-80 nucleotides (He and Taussig, 2005). An 
extension primer (EP1) was thus designed  (5’- GCT ACC GCC TCC ACT CCC ACC 
GCC AGA TCC CCC ACC CGA GCC TCC CCC TGA ACC GCC TCC CCG GGA 
TGC GGC CGC RGT RTC CTT GG -3’), which covers the missing 60-80 nucleotides. 
Using the primers T7AB and EP1, a full-length DNA construct was obtained by PCR. 
The generated full-length DNA is directly used for the subsequent cycle of ribosome 
display.  
 
 
2.3.2 Antigen coating 
 
10 µg of antigen (recombinant gp120) in a volume of 20 µl was used to coat a 0.2 ml 
PCR tube at 4°C overnight. After washing twice with 100 µl of phosphate buffered 
saline (PBS, 137 mM NaCl, 2.5 mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4, pH 
7.4), the PCR tube was blocked with 100 µl of 10 mg/ml BSA in PBS at room 
temperature for 1 hour. The PCR tube was then washed by 100 µl of PBS three times 
followed by ribosome display washing buffer (PBS containing 0.01% Tween 20, 5 mM 
Mg acetate and 0.1% BSA, pH 7.4) and kept at 4°C before use. 
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Figure 2.3 Ribosome display flow chart 
 (1) cDNA library mixture is extended at 3’ end to generate the full-length construct by 
PCR; (2) in vitro coupled transcription/translation is set up, individual antibody 
fragments are generated through ribosome-directed protein synthesis and physically 
linked with its translating mRNA due to the absence of the stop codon; (3) Antibody-
Ribosome-mRNA (ARM) complex is added to antigen gp120-coated tube for in vitro 
selection, unbound ARM complexes are washed away; (4) RT-PCR recovery of cDNA 
from selected mRNA sequences, single primer PCR is set up to amplify the sequences 
with primer Kz1; (5) full-length cDNA is regenerated by PCR, which can be used as 
template for the subsequent round of ribosome display or cloning for E. coli 
expression. 
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2.3.3 Coupled transcription/translation 
 
In vitro coupled transcription/translation was performed with TNT® T7 Quick 
Coupled Transcription/Translation System. The reaction was set up by mixing 20 µl of 
TNT T7 Quick Master Mix, 0.5 nmol of methionine (both provided in the kit), 50 nmol 
of Mg acetate, 0.1-1 µg of DNA (product from section 2.3.1) and DEPC-treated H2O 
making up to a final volume of 25 µl, and incubating at 30°C for 60 minutes. In order 
to remove input DNA, 60 units of DNase I were added to the TNT mixture and 
incubated at 30°C for 20 minutes. Then the mixture was diluted with 35 µl of cold PBS 
containing 5 mM of Mg acetate before transferring to antigen-coated PCR tube, and 
incubating at 4°C for 2 hours.  
 
 
2.3.4 cDNA recovery by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
 
After washing 5 times with ice cold ribosome display washing buffer and 2 times with 
cold distilled H2O, the PCR tube was treated with 8 µl of DEPC-treated H2O heated at 
75°C for 10 minutes; then 20 nmol of deoxyribonucleotide triphosphate (dNTP, 
provided in ProtoScript ® First Strand cDNA Synthesis Kit) and 20 pmol of primer 
IP1 were added to the tube and heated at 70°C for 5 minutes, followed by rapid cooling 
on ice for at least 30 seconds. RT-PCR recovery was performed with ProtoScript ® 
First Strand cDNA Synthesis Kit, by adding 200 units of M-MuLV reverse 
transcriptase, 10 units of RNase inhibitor (both provided in the kit), 10 nmol of 
dithiothreitol and DEPC-treated H2O to make up to a final volume of 20 µl. The 
mixture was incubated at 42°C for 75 minutes followed by 80°C for 5 minutes. The 
cDNA generated was ready for amplification by single primer PCR (figure 2.4). 
 
 
2.3.5 Single primer PCR and generation of full-length cDNA construct 
 
Single primer PCR was carried out with 10 µl of 5X Taq & Go Ready to Use PCR 
Mix, 50 pmol of primer Kz1, 2 µl of recovered cDNA as template and DEPC-treated 
H2O to a final volume of 50 µl. The cycling was carried out by: one cycle of initiation 
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at 94°C for 5 minutes, 30 cycles of 94°C for 30 seconds, 48°C for 30 seconds and 72°C 
for 1 minute, and finally, one cycle at 72°C for 10 minutes. 1 µl of the PCR product 
was used as the template to carry out another 30 cycles PCR under the same condition 
to further amplify the selected cDNA. The second PCR product was analysed by gel 
electrophoresis and purified with QIAquick Gel Extraction Kit. Purified cDNA product 
was used as template to extend the cDNA fragment to full-length and introduce 
restriction site NotI at the 3’ end, with 25 pmol of each primer T7AB and LP1 and 
annealing temperature at 55°C. The regenerated full-length cDNA can be used as 
template in additional rounds of ribosome display or E. coli cloning. 
 
 
 
 
Figure 2.4 Primer design for in situ reverse transcription and single primer 
amplification 
Primer IP1 was designed to introduce a 15 bp Kozak sequence to the 3’ end of mRNA, 
leading to the generation of single-stranded cDNAs with a complementary flanking 
sequence at both 5’ and 3’ ends, which can be amplified with a single primer Kz1. 
Kozak sequence (bold) and T7 sequence (underlined) are shown. 
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2.4 Cloning and DNA sequencing 
 
 
2.4.1 Chemically competent cell preparation 
 
Chemically competent XL1-blue and BL21(DE3)pRARE cells were prepared using the 
Cohen method (Cohen et al., 1972). In brief, 5 single colonies of E. coli cultured on 
Luria Bertani (LB) agar (containing 12.5 µg/ml of tetracycline for XL1-blue strain and 
25 µg/ml of chloramphenicol for BL21(DE3)pRARE strain) were transferred into 10 
ml of LB media and grown at 37°C, 250 rpm overnight. The culture was then added 
into 200ml of fresh LB media supplemented with the required antibiotics. The culture 
continued to grow at 37°C, 250 rpm until optical density (OD)600 was 0.4 to 0.5. After 
cooling down on ice for 30 minutes, the culture was split in 50 ml volumes into four 
centrifuge tubes and subsequently centrifuged at 1000 g for 7 minutes at 4°C. Each 
pellet was resuspended in 12.5 ml of cooled 100 mM MgCl2 and centrifuged at 1000 g 
for 7 minutes at 4°C. Then 25 ml of cooled 100 mM CaCl2 was added to each pellet 
and the mixture was left on ice for 30 minutes, followed by centrifugation at 1000 g for 
7 minutes at 4°C. Finally, each pellet was resuspended in 1 ml of 100 mM CaCl2 
containing 15% glycerol, and aliquots (50 µl) were flash frozen in dry ice and stored at 
-80°C. 
 
 
2.4.2 Cloning, digestion and ligation  
 
TOPO cloning was used to clone the PCR product selected by ribosome display. The 
reaction was set up with TOPO TA Cloning® Kit according to manufacturer’s 
instructions. 4 µl of DNA recovered from ribosome display selection was ligated into 1 
µl of TOPO vector and 1 µl of salt solution (provided in TOPO TA Cloning® Kit for 
Sequencing) and incubated at room temperature for 1 hour, before transforming into 
XL1-blue competent cells for blue/white colony screening. Plasmid DNA from 
positive colonies was extracted for sequencing (see below). 
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To express selected scFv in E. coli, restriction enzyme digestion followed by ligation 
into expression vector was performed as following: 30 µl of purified DNA was 
incubated with 5 units of each restriction enzyme NcoI and NotI in the presence of 1X 
NEBuffer 3, 100 µg/ml BSA and H2O to a final volume of 50 µl. The reaction mixture 
was incubated at 37°C for 3 hours. Digested product was examined by gel 
electrophoresis on 2% (w/v) agarose gel, and subsequently purified with QIAquick Gel 
Extraction Kit, as described in section 2.2.3. 
 
After digestion with restriction enzymes NcoI and NotI, the scFv was inserted into 
expression vector pSANG10-3F, which was also digested with the same restriction 
enzymes NcoI and NotI. Ligation reaction was set up by mixing 7 µl of purified scFv, 1 
µl of purified pSANG10-3F, 1 µl containing 20 units of T4 DNA ligase and 1 µl of 
10X T4 DNA ligase reaction buffer making up to a final volume of 10 µl. The reaction 
mixture was incubated at room temperature for 1 hour before transforming into XL1-
blue competent cells. Positive plasmid DNA was identified and used to transform 
BL21(DE3)pRARE cells for protein expression. 
 
Since the use of pSANG 10-3F vector requires two transformation steps prior to 
protein expression, an alternative vector was constructed to allow single transformation 
and immediate production. pABEXT vector was created by double digesting pMAL-
c2X vector with restriction enzyme NdeI and HindIII, and ligating the insert between 
the NdeI and HindIII sites of pSANG10-3F vector (Figure 2.5). The constructed 
pABEXT vector encodes tac promoter (de Boer et al., 1983) and PelB leader sequence 
(Milstein et al., 1972). The tac promoter facilitates protein expression in E. coli XL1-
blue strain, while the PelB leader sequence enables protein secretion into periplasm of 
E. coli therefore crude extract of secreted proteins can be tested quickly in ELISA. A 
full sequence of pABEXT vector is shown in the appendix 2. 
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Figure 2.5 Construction of pABEXT vector 
pABEXT vector was constructed by using pMAL-c2X vector as backbone, and 
inserting the fragment between NdeI and HindIII sites of pSANG10-3F vector. The 
constructed pABEXT vector consists tac promoter and PelB leader sequence, and both 
6XHis-tag and tri-FLAG-tag for protein purification and detection. 
 
	   	   	  64	  
2.4.3 E. coli transformation 
 
For DNA cloning, TOPO ligation mixture was transformed into XL1-blue competent 
cells on X-gal plate to perform blue/white screening. 50 µl of XL1-blue competent 
cells were thawed on ice for 5 minutes and added 6 µl of TOPO ligation mixture. After 
incubation on ice for 5 minutes, the cells were heat shock in a 42°C water bath for 1 
minute, followed by placing the tube on ice for 5 minutes. 250 µl of pre-warmed SOC 
(20 mg/ml Bactotryptone, 5 mg/ml Yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgSO4, 10 mM MgCl2, 0.4% glucose, pH 7.0) was added to the tube and incubated at 
37°C, 250 rpm for 1 hour. All the mixture was plated on X-gal plate (LB agar 
containing 40 µg/ml of X-gal, 200 µM of IPTG and 100 µg/ml of carbenicillin) and 
incubated at 37°C overnight. 
 
For protein expression, the pSANG and scFv ligation mixture was transformed into 
XL1-blue competent cells on LB agar plate supplemented with 50 µg/ml of kanamycin 
using the same protocol as described above. 
 
 
2.4.4 Plasmid DNA miniprep and DNA sequencing 
 
Clones identified from X-gal plate was grown in 10 ml of LB media supplemented 
with 100 µg/ml carbenicillin at 37°C, 250 rpm overnight. The overnight culture was 
centrifuged at 1000 g for 10 minutes, and plasmid DNA was isolated from cells using 
QIAprep® Spin Miniprep Kit according to manufacturer’s instructions. In brief, the 
cell pellet was resuspended in 250 µl of P1 buffer (50 mM Tris-HCl, 10 mM EDTA, 
50 µg/ml RNase, pH 8.0) and transferred into a 1.5 ml micro-centrifuge tube. The cells 
were lysed by adding 400 µl of P2 buffer (0.2 M NaOH, 1% SDS) and inverting the 
tube 5 times. The solution was neutralised by adding 580 µl of N3 buffer (4 M 
guanidine hydrochloride, 0.5 M potassium acetate, pH 4.2) and inverting the tube 5 
times. The mixture was centrifuged at 13000 g for 10 minutes, and the supernatant was 
carefully transferred to QIAprep spin column and centrifuged at 13000 g for 1 minute. 
Then the column was washed once with 500 µl of PB buffer (5 M guanidine 
hydrochloride, 20 mM Tris-HCl, 38% ethanol, pH 6.6), followed by 750 µl of PE 
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buffer (20 mM NaCl, 2 mM Tris-HCl, 80% ethanol, pH 7.5). After discard the flow-
through, the column was centrifuged at 13000 g for 1 minute again to remove residual 
wash buffer. Purified DNA was eluted by adding 30 µl of DEPC-treated H2O and 
centrifuged at 13000 g for 1 minute.  
 
Purified plasmid DNA was sequenced at the Wolfson Institute for Biomedical 
Research, University College London using primers M13-20 (5'-GTA AAA CGA 
CGG CCA GT-3') and M13 rev (5'-GGA AAC AGC TAT GAC CAT G-3'). 
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2.5 Protein expression and purification 
 
 
2.5.1 Protein expression with pSANG vector 
 
Clones of interest were expressed as scFv after DNA sequencing. DNA was amplified 
by PCR using primer T7AB (5’- GC AGC TAA TAC GAC TCA CTA TAG GAA 
CAG ACC ACC ATG GCC -3’) and reverse primer TJ011 (5’- GCC CGC GGC CGC 
TGT GCC CCC AGA GGT G -3’, for IgG1 sequences), or TJIgG24 (5’- GCC CGC 
GGC CGC TGT GCT CTC GGA GGT G -3’, for IgG2, IgG4 sequences). After 
digestion with restriction enzymes NcoI and NotI, the scFv was inserted into 
expression vector pSANG10-3F and transformed into XL1-blue competent cells. 
Positive plasmid DNA was identified and used to transform BL21(DE3)pRARE cells 
for protein expression. 
 
BL21(DE3)pRARE was chosen for expressing antibody scFv as mentioned in 1.1.11.  
5 single colonies from LB agar supplemented with 50 µg/ml of kanamycin and 25 
µg/ml of chloramphenicol were grown in 10 ml of LB media at 37°C, 250 rpm 
overnight with required antibiotics. Before induction, 700 µl of overnight culture was 
made a bacterial stock by mixing with 300 µl of 50% glycerol and stored at -80°C. The 
remaining culture was used for protein expression by adding into 200 ml of fresh LB 
media supplemented with appropriate antibiotics. The culture was grown at 37°C, 250 
rpm until OD600 reached 0.5, and then incubated on ice for 30 minutes. To make an 
uninduced sample as the control, 1 ml of culture was taken out and centrifuged at 
13000 g for 1 minute. Protein expression was induced by adding IPTG into the culture 
at the final concentration of 0.3 mM and the culture was incubated at 20°C, 250 rpm 
for 20 hours. 1 ml of the induced culture was collected for protein analysis (section 
2.5.5). 
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2.5.2 Protein expression with pABEXT vector 
 
To facilitate a high throughput, an alternative expression strategy was performed using 
pABEXT vector. Selected cDNA from ribosome display was digested with NcoI and 
NotI directly (figure 2.6). Single-chain product (VL-link-VH-CH1-hinge-partial CH2) 
at the size of approximately 1200 bp was ligated into pABEXT vector. Proteins were 
expressed in 50 ml scale with the method described in section 2.5.1, and extracted by 
osmotic shock (see 2.5.3). The crude extract was used to perform ELISA against 
recombinant gp120 as described in 2.6.1. Positive clones were subsequently sequenced 
with primer M13-20, and standard protocol performed with these clones as described 
above. 
 
 
 
2.5.3 Purification of proteins from E. coli periplasm (osmotic shock) 
 
The proteins expressed in the periplasm of E. coli were extracted by osmotic shock, 
and subsequently purified with a column supplemented with Nickel chelating resin, as 
described in The QIAexpressionistTM -- A handbook for high-level expression and 
purification of 6xHis-tagged proteins, fifth edition. Basically, the cells from a 200 ml 
culture were collected by centrifugation at 3000 g for 20 minutes at 4°C. The cell pellet 
was resuspended in 5 ml of TES buffer [30 mM Tris base, 1 mM 
Ethylenediaminetetraacetic acid (EDTA), 20% sucrose, pH 8.0]. The cells were 
incubated on ice for 10 minutes and centrifuged at 9000 g for 20 minutes at 4°C. The 
supernatant (periplasmic fraction 1) was collected and stored on ice, while the cell 
pellet was resuspended in 5 ml of 5 mM MgCl2. After incubating for 10 minutes on 
ice, the suspension was centrifuged at 9000 g for 20 minutes at 4°C. The supernatant 
(periplasmic fraction 2) was collected and mixed with periplasmic fraction 1. 
Remaining cell pellets were analysed for the non-secreted recombinant protein 
expression.  
 
The periplasmic fractions were subsequently purified using a Ni-NTA column, which 
was equilibrated with lysis buffer (50 mM NaH2PO4, 500 mM NaCl, 10 mM 
imidazole, pH 8.0). At the same time, 3.3 ml of 4X lysis buffer (200 mM NaH2PO4, 2 
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M NaCl, 40 mM imidazole, pH 8.0) was added to the supernatant, which was then 
loaded to the column. The column was washed with 5 ml of wash buffer (50 mM 
NaH2PO4, 500 mM NaCl, 20 mM imidazole, pH 8.0), and the protein was eluted with 
0.5 ml of elution buffer (50 mM NaH2PO4, 500 mM NaCl, 500 mM imidazole, pH 8.0) 
by 5 times. Purified proteins were flash frozen on dry ice and stored at -20°C. 
 
 
2.5.4 Purification of proteins from E. coli total extracts  
 
Recombinant proteins were also extracted from total cell lysate of E. coli and affinity 
purified with Ni-NTA spin columns using the protocol described in Ni-NTA Spin Kit 
Handbook, second edition and The QIAexpressionistTM -- A handbook for high-level 
expression and purification of 6xHis-tagged proteins, fifth edition. Briefly, the cells 
from 200 ml culture were collected by centrifugation at 3000 g for 20 minutes at 4°C. 
The cell pellet was resuspended in 5 ml of lysis buffer (50 mM NaH2PO4, 500 mM 
NaCl, 10 mM imidazole, pH 8.0). 500 µg of lysozyme and 5 µmol of 
phenylmethanesulfonyl fluoride (PMSF) were added to the suspension, in order to 
break E. coli cell walls and inhibit protease. The cell membrane was disrupted by 
sonicating the suspension for 30 seconds by 6 times using an ultrasonic probe, 
followed by incubating on ice for 1 hour. Soluble protein was collected by performing 
centrifugation at 19000 g for 45 minutes at 4°C, and transferring supernatant to a fresh 
tube. Recombinant protein was subsequently purified by Ni-NTA spin column, which 
was equilibrated with 600 µl of lysis buffer before use. The supernatant was loaded to 
spin column and centrifuged at 2000 g for 2 minutes at 4°C. The column was washed 
with 600 µl of wash buffer (50 mM NaH2PO4, 500 mM NaCl, 20 mM imidazole, pH 
8.0). Finally, protein was eluted in 100 µl of elution buffer (50 mM NaH2PO4, 500 mM 
NaCl, 500 mM imidazole, pH 8.0) by 5 times.  
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Figure 2.6 Antibody expression in two vectors 
Ribosome display selected antibodies were expressed either in pSANG vector in the 
form of scFv, or in pABEXT vector in the form of single-chain for a quick screening 
purpose. Note antibodies were expressed at different sizes because of the two different 
methods. 
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To remove the excess salt from eluted proteins, centrifugal filter units was used to 
desalt and also concentrate the purified proteins according to the manufacturer’s 
instructions. Eluted protein fractions were mixed and loaded to Amicon filter column, 
and centrifuged at 13000 g for 15 minutes at 4°C to remove most of the solvent. The 
remaining solution was diluted with 450 µl of PBS, followed by centrifugation at 
13000 g for 15 minutes at 4°C. The column was inverted in a clean collection tube, and 
centrifuged at 1000 g for 2 minutes at 4°C to collect concentrated and desalted protein. 
Protein concentration was determined by Nanodrop 1000 spectrophotometer in 
accordance with manufacturer’s instructions. The proteins were flash frozen and stored 
at -80°C. 
 
 
2.5.5 Electrophoresis analysis of scFv proteins 
 
Recombinant proteins purified by the methods described in section 2.5.3 and 2.5.4 
were analysed by Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and western blotting. SDS-PAGE was prepared using Laemmli system 
(Laemmli, 1970) with some modifications. 12% Resolving gel [12% acrylamide/bis 
(29:1), 360 mM Tris base, 0.1% SDS, 0.1% ammonium persulphate, 0.1% TEMED, 
pH 8.8] and 4% Stacking gel [4% acrylamide/bis (29:1), 60 mM Tris base, 0.1% SDS, 
0.1% ammonium persulphate, 0.1% TEMED, pH 6.8] were used to detect protein 
fragments. Cell pellets (uninduced and induced samples from section 2.5.1) were 
dissolved in 50 µl of 4X protein gel loading buffer (62.5 mM Tris base, 2% SDS, 5% 
β-mercaptoethanol, 0.05% Bromophenol blue, 10% glycerol, pH 6.8) and heated at 
95°C for 5 minutes. 36 µl of other samples from protein purification (soluble fraction, 
flow-through, wash fraction and elution1-4) were diluted with 12 µl of 4X protein gel 
loading buffer and heated at 95°C for 5 minutes. Typically 20 µl (10 µl for uninduced 
and induced samples) was loaded on each well of the gel, while 5 µl of protein marker 
was used as standards. Electrophoresis was performed using a Mini-PROTEAN Tetra 
Electrophoresis System with running buffer (25 mM Tris base, 192 mM glycine, 0.1% 
SDS), and 200 volts were applied for 45 minutes. Gels after SDS-PAGE can be used 
for Coomassie blue staining or for western blotting. 
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For Coomassie blue staining (Meyer and Lamberts, 1965), the proteins were visualised 
on gels by dye staining using the solution containing 0.025% (w/v) Coomassie brilliant 
blue R-250 in 10% (v/v) acetic acid, in a microwave until boiling followed by 1 minute 
on rocking table. Finally, the gel was destained using 10% (v/v) acetic acid by boiling 
in a microwave.  
 
For western blotting, the proteins were transferred from the gel to Immobilon-P 
transfer membrane using a Mini Trans-Blot Cell with transfer buffer (25 mM Tris base, 
192 mM glycine, 20% methanol) (Towbin et al., 1979), and 100 volts were applied for 
1 hour. The membrane was blocked with 2% milk powder (Tesco)/PBS at room 
temperature for 1 hour. After washing with Tris buffered saline Tween 20 (TBST, 50 
mM Tris base, 150 mM NaCl, 0.1% Tween 20, pH 7.4) twice, the membrane was 
incubated with monoclonal anti-polyHistidine-alkaline phosphatase antibody produced 
in mouse (1: 20000 diluted in 2% milk/PBS) at room temperature for 2 hours. The 
membrane was then washed 5 times with TBST, and protein bands were visualised by 
adding substrate [0.02% BCIP and 0.03% NBT in AP buffer (100 mM Tris-HCl, 100 
mM NaCl, 5 mM MgCl2, 0.05% Tween 20, pH 9.5)] and incubating at room 
temperature for 2 to 5 minutes.  
 
Protein markers were used for SDS-gel and western blotting. They were made by 
mixing 4 recombinant proteins together: pET32a plasmid (20 kDa), Red Fluorescent 
Protein (RFP) in pSANG (30 kDa), MopB protein in pSANG (42 kDa) and Heat Shock 
Protein (HSP) 70 in pET16b (75 kDa). These protein standards were confirmed by 
comparing with commercial Precision plus protein dual Xtra standards in SDS-PAGE 
and western blotting.  
 
 
	   	   	  72	  
2.6 Functional assays 
 
 
2.6.1 ELISA 
 
Antibody binding to recombinant gp120 was examined by Enzyme-linked 
immunosorbent assay (ELISA). F96 MaxiSorp Nunc-Immuno plates were coated with 
100 µl of 1 µg/ml of gp120 in PBS overnight. As a negative control, 100 µl of 1 µg/ml 
of BSA/PBS was coated. Plates were blocked with 2% milk/PBS at room temperature 
for 1 hour, followed by washing with TBST 5 times. Purified antibodies diluted at 5-25 
µg/ml in PBS were incubated in the wells at room temperature for 2 hours. Plates were 
washed with TBST for 5 times before adding monoclonal anti-polyHistidine-alkaline 
phosphatase antibody (1: 10000 diluted in 2% milk/PBS) at room temperature for 2 
hours. The assay was developed with 1 mg/ml pNPP in 0.2 M Tris (pH 8.0). After 
incubating at room temperature for 2 hours, the absorbance at 405 nm was measured 
using a VICTOR plate reader. Both sample and control were performed in triplicate. 
 
 
2.6.2 Neutralisation assay 
 
The neutralisation assay was performed at the Centre for Infectious Disease, Blizard 
Institute of Cell and Molecular Science, Barts and The London, Queen Mary, 
University of London. The neutralising activity was measured by luciferase-based 
assay in TZM-bl cell (Li et al., 2005). Antibodies were tested at the starting 
concentration of 50 µg/ml followed by two 4-fold dilutions in 50 µl of Dulbecco's 
modified Eagle medium (DMEM) with 10% Foetal calf serum (FCS) in a 96 well flat 
bottom opaque Nunc plate. 50 µl of virus prepared from replication competent HIV-1 
molecular clones was added and left at 37°C for 1 hour. 104 TZM-bl cells in 100 µl of 
DMEM with 10% FCS, containing 50 µg/ml of Diethylaminoethyl (DEAE)-dextran, 
were added to the virus-antibody mixtures. Wells with protein elution buffer (i.e. PBS) 
were included as virus control (cell + virus), and wells with cells alone were included 
as the cell control. Neutralising plasma (1:20 dilution) from patient K530 was used as 
the positive control. After incubation at 37°C for 48 hours, 150 µl of the medium was 
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removed from each well. 50 µl of Bright-GLo Luciferase reagent was added to 
remaining cells and incubated for 2 minutes. Luminescence was measured using a 
FLUOstar OPTIMA. Neutralisation percentage was calculated as 100 X [1 - (sample 
luminescence / virus control luminescence)] after the cell alone control luminescence 
was subtracted.  
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Chapter 3  
 
Results 
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3.1 Construction of single-chain antibody libraries 
 
 
3.1.1 Construction of the single-chain antibody library from patient M325  
 
 A total of 98 µg RNA was isolated from 100 ml of blood of donor M325 and 20 µg 
RNA was from 20 ml of blood of donor K530. Both RNA samples were used as the 
template to generate required cDNA synthesis followed by PCR amplification of 
individual Vλ, Vκ and heavy chain using specific primers designed (see the materials 
and methods). 
 
Figure 3.1 shows the PCR production of individual Vκ and Vλ light chain fragments 
from patient M325 using antibody family-specific primers. DNA bands with expected 
size were excised and recovered. 
 
 
 
Figure 3.1 PCR products of 4 Vκ chains and 9 Vλ chains in library M325 
Lane 1, 100bp ladder; lane 2, Vκ1; lane 3, Vκ2346; lane 4, Vκ36; lane 5, Vκ5; lane 6, 
Vλ1; lane 7, Vλ1459; lane 8, Vλ15910; lane 9, Vλ2; lane10, Vλ3A; lane 11, Vλ3B; 
lane 12, Vλ3DLP16; lane 13, Vλ6; lane 14, Vλ78. The expected size of products (~380 
bp) is indicated.  
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However, PCR generation of VH from the synthesised cDNA only led to production of 
about 50% of the VH families with the expected size, while the rest failed to produce 
detectable bands. To solve this problem, one-step RT-PCR, in which the reverse 
transcription is coupled with PCR, was performed, leading to the successful generation 
of all the VH families using the identical set of primers directly from mRNA template 
in the total RNA extract (figure 3.2). The heavy chains (780bp) were identified, based 
on their sizes. Despite some non-specific PCR bands were also detected on the gel, the 
correct-sized bands were eluted, pooled and used for DNA assembly (see below). 
 
 
 
Figure 3.2 PCR products of 8 heavy chains in library M325 
Lane 1, 100bp ladder; lane 2, VH1; lane 3, VH1257; lane 4, VH2; lane 5, VH3A; lane 
6, VH3B; lane 7, VH4; lane 8, VH4DP63; lane 9, VH6. The expected size of the 
products (~780 bp) is indicated. 
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Both the eluted light chains and heavy chains were then combined and assembled 
individually. Analysis by gel electrophoresis shows the successful linkage of light 
chains with heavy chains. Interestingly, VHs linked with kappa chains gave stronger 
bands than the VHs linked with lambda chains. A representative gel picture (Vκ and 
Vλ linked with VH1) is shown as figure 3.3. The assembled fragments were pooled 
and stored for use. This library was called Library M325. 
 
 
 
Figure 3.3 PCR products of Vκ-VH1 and Vλ-VH1 combinations in library M325   
Combinations with VH1 families are chosen to illustrate the single-antibody library 
M325 construction. Lane 1, 100bp ladder; lane 2, Vκ1-VH1; lane 3, Vκ2346-VH1; 
lane 4, Vκ36-VH1; lane 5, Vκ5-VH1; lane 6, 100bp ladder; lane 7, Vλ1-VH1; lane 8, 
Vλ1459-VH1; lane 9, Vλ15910-VH1; lane 10, Vλ2-VH1; lane 11, Vλ3A-VH1; lane 
12, Vλ3B-VH1; lane 13, Vλ3DLP16-VH1; lane 14, Vλ6-VH1; lane 15, Vλ78-VH1. 
The expected size of the products (~1200 bp) is indicated. 
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3.1.2 Construction of the single-chain antibody library from patient K530  
 
An alternative library from patient K530 was also constructed using the same 
procedure described for the library M325 in 3.1.1, with following modifications: VL, 
VH fragments from first 30 cycles of PCR were separated on an agarose gel, purified 
and then used as the template for amplification by PCR for further 30 cycles using the 
same set of primers. Subsequent combinations were carried out using the same 
protocol as the library M325, using purified DNA from second round of PCR as 
templates. Figure 3.4, 3.5 and 3.6 show the gel analysis of the assembled DNA 
fragments with the expected sizes, indicating correct construction of the library in the 
form of VL-link-VH-CH1-hinge-partial CH2 as designed. 
 
 	   	    
 
Figure 3.4 PCR products of 4 Vκ chains and 9 Vλ chains in library K530 
Lane 1, 100bp ladder; lane 2, Vκ1; lane 3, Vκ2346; lane 4, Vκ36; lane 5, Vκ5; Lane 6, 
100bp ladder; lane 7, Vλ1; lane 8, Vλ1459; lane 9, Vλ15910; lane 10, Vλ2; lane 11, 
Vλ3A; lane 12, Vλ3B; lane 13, Vλ3DLP16; lane 14, Vλ6; lane 15 Vλ78. Products are 
from two rounds of 30 cycles PCR. The expected size of products (~380 bp) is 
indicated.  
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Figure 3.5 PCR products of 8 heavy chains in library K530 
Lane 1, 100bp ladder; lane 2, VH1; lane 3, VH1257; lane 4, VH2; lane 5, VH3A; lane 
6, VH3B; lane 7, VH4; lane 8, VH4DP63; lane 9, VH6. Products are from two rounds 
of 30 cycles PCR. The expected size of the products (~780 bp) is indicated. 
 
	    
   
Figure 3.6 PCR products of Vκ-VH1 and Vλ-VH1 combinations in library K530 
Combinations with VH1 families are chosen to illustrate the single-antibody library 
K530 construction. Lane 1, 100bp ladder; lane 2, Vκ1-VH1; lane 3, Vκ2346-VH1; lane 
4, Vκ36-VH1; lane 5, Vκ5-VH1; lane 6, 100bp ladder; lane 7, Vλ1-VH1; lane 8, 
Vλ1459-VH1; lane 9, Vλ15910-VH1; lane 10, Vλ2-VH1; lane 11, Vλ3A-VH1; lane 
12, Vλ3B-VH1; lane 13, Vλ3DLP16-VH1; lane 14, Vλ6-VH1; lane 15, Vλ78-VH1. 
The expected size of the products (~1200 bp) is indicated. 
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3.2 Ribosome display and antibody selection 
 
Individual PCR libraries were combined and extended at the 3’ end with a spacer for 
ribosome display as described in section 2.3.1. The full-length PCR products (about 
1225 bp) were added into TNT coupled reticulocyte lysate and the mixture was 
incubated at 30°C for 1 hour to generate ARM complexes. The translation mixture was 
then added into wells coated with 0.5 mg/ml of antigen gp120 for additional one hour. 
After washing, the bound ARM complexes on wells were directly subjected to in situ 
RT-PCR to recover the selected genetic information. Recovered PCR product was 
analysed by agarose gel electrophoresis (Figure 3.7).  
 
In a preliminary selection, no RT-PCR product was detected after 30 cycles of PCR, 
while product can be seen with 40 cycles of PCR. This indicates that the DNA 
fragment being selected is rare and thus, further cycles are required. However, stop 
codons were observed in the PCR products after 40 cycles, indicating that too many 
PCR cycles may have introduced mutations into the DNA fragments (i.e., when dNTPs 
in the PCR reaction become limiting, the error rate of the Taq polymerase increases). 
This problem has been avoided by performing the first PCR by 30 cycles, followed a 
second PCR of 30 cycles with replenished dNTPs. DNA sequencing shows no stop 
codon generated in this method. 
 
In order to increase the recovery sensitivity, an in situ RT-PCR procedure developed 
by He and Taussig was performed using a single-primer (He and Taussig, 2007). In 
this method, an internal primer IP1 was designed to contain both a sequence for 
hybridising to the upstream region of 3’ mRNA (to avoid the stalling ribosome) and a 
sequence identical to the 5’ region of mRNA (as illustrated in figure 2.4). cDNA 
synthesis using IP1 leads to the generation of single-stranded cDNAs with a 
complementary flanking sequence at both 5’ and 3’ ends, which can be effectively 
amplified by PCR using a single primer (He and Taussig, 2007). As the internal primer 
IP1 anneals at 28 amino acids upstream of the C terminal, the PCR product recovered 
was 75bp shorter than original full-length size. In order to perform the subsequent 
ribosome display cycle, the recovered PCR fragment was then extended by second 
PCR with long primers T7AB and LP1 to add the T7 promoter and protein initiation 
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elements, as well as extend the 3’end into the full-length product (1225bp) (Figure 3.7, 
right). 
 
 
 
 
Figure 3.7 PCR products after one round of ribosome display 
PCR products after 1 round of ribosome display were run on 1.5% (w/v) agarose gels. 
The expected size of the amplified product with single-primer Kz1 is  ~1150 bp, and 
the expected size of the full-length product amplified with T7AB and LP1 is ~1225 bp. 
DNA bands shown in rectangles were excised from the agarose gel and purified as 
described in section 2.2.3. Lane 1, 100 bp ladder; lane 2, single-primer PCR product 
after 1 round of ribosome display against antigen gp120 from library M325; lane 3, 
single-primer PCR product after 1 round of ribosome display against BSA from library 
M325 (negative control); lane 4, 100 bp ladder; lane 5, single-primer PCR product 
after 1 round of ribosome display against antigen gp120 from library K530; lane 6, 
single-primer PCR product after 1 round of ribosome display against BSA from library 
K530 (negative control); lane 7, 100 bp ladder; lane 8, full-length PCR product using 
DNA purified from lane 2 as template (~1225 bp); lane 9, amplification of DNA 
purified from lane 2 with primer Kz1 (~1150 bp, to compare with lane 8). 
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To select antibodies against gp120, three rounds of ribosome display were initially 
performed using the library M325. However, sequence analysis of 3 random selected 
clones revealed the same sequence among them, indicating a strong enrichment of this 
sequence in the three-cycle selection. In order to select more diverse antibodies, a 
single round of ribosome display was carried out from both libraries M325 and K530. 
Ribosome selected cDNA products were cloned into E. coli XL1-blue and screened for 
blue/white clones on a X-gal plate. Table 3.1 lists the CDR3 sequence analysis of 10 
representative clones (7 from library M325 and 3 from library K530), which reveals 
that most of selected clones fall into several groups with very similar CDRs in both 
light chains and heavy chains, suggesting the selection worked. Interestingly, a 
sequence with the identical CDR3 of both light and heavy chains were identified with 
two clones from each of the two libraries (clones 011, 1-5 from library M325 and 
clones 2-2, 2-4 from library K530) (Table 3.1).   
 
IMGT website was used to analyse the sequences (Giudicelli et al., 2004). When 
aligning with online database, all the Vκ and VH domains have shown 99-100% 
similarities to published anti-HIV antibodies (Altschul et al., 1990). In contrast, no 
similar sequence of anti-HIV antibody was found for Vλ domains. Based on antibody 
subclasses, 7 out of 10 show the sequences of IgG1, and the rest belong to IgG2 or 
IgG4 families. The selected antibody families and subclasses are listed in table 3.2. 
Full DNA sequences of the selected 10 antibodies are shown in the appendix 3. 
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Table 3.1 
  Light chain Heavy chain 
Library Clone CDR3 FR4 CDR3 FR4 
011 QQYSASSST FGQG ARLAVDTVMVQGYFDL WGQG 
1-1 QSYDNRNQI FGGG VRQSLDNYAYHLDY WGQG 
1-5 QQYSASSST FGQG ARLAVDTVMVQGYFDL WGQG 
1-7 QSYEASSHEWV LGGG ARDEVTGTGVLDY WGQG 
I3 QRYGSSPRA FGPG ARDHVDTPMGLDY WSQG 
I4 QRYGSSPRA FGPG ARDHVDTPMGLDY WSQG 
M325 
M5 QAWDSSTVV SGGG ARQGYTHRDVLTRQKFYFYYMDV WGKG 
2-1 QSYDNRNQI FGGG VRQSLDNYAYHLDY WGQG 
2-2 QQYSASSST FGQG ARLAVDTVMVQGYFDL WGQG K530 
2-4 QQYSASSST FGQG ARLAVDTVMVQGYFDL WGQG 
 
Table 3.1 CDR3 sequences of the selected antibodies 
DNA sequencing of the selected clones from one round of ribosome display reveals 
their CDR3 and framework (FR) 4 sequences. Clones 011, 1-5 from library M325 and 
clones 2-2, 2-4 from library K530 show identical CDR3 sequences (shaded in blue), 
and clone 1-1 from library M325 appears to have same CDR3 sequence as clone 2-1 
from library K530 (shaded in yellow). 
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                                                             Table 3.2 
Library Clone VL family VH family Subclass 
011 Vκ1 VH2 IgG1 
1-1 Vλ6 VH3A IgG4 
1-5 Vκ1 VH2 IgG1 
1-7 Vλ6 VH6 IgG1 
I3 Vκ1 VH1 IgG1 
I4 Vκ1 VH1 IgG1 
M325 
M5 Vλ6 VH6 IgG4 
2-1 Vλ6 VH3A IgG2 
2-2 Vκ1 VH2 IgG1 K530 
2-4 Vκ1 VH2 IgG1 
 
Table 3.2 VL, VH families and subclasses of the selected antibodies 
DNA sequencing of the selected clones from one round of ribosome display reveals 
that the antibodies fall into several groups of VL, VH families and subclasses. E.g., 
clones 011, 1-5 from library M325 and clones 2-2, 2-4 from library K530 belong to the 
same VL, VH families and subclass (shaded in blue); clones I3 and I4 from library 
M325 belong to the same group (shaded in green); while clone 1-1 from library M325 
and clone 2-1 from library K530 have the same VL, VH families, but different 
subclasses (shaded in yellow). 
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3.3 Protein expression and purification  
 
 
3.3.1 Calibration of protein markers 
 
In order to facilitate detection and monitoring protein size, especially in western 
blotting probed by an anti-His-tag antibody, His-tagged protein standard was created in 
our lab.  Four known recombinant proteins [pET32a plasmid (20kDa), RFP (30kDa), 
MopB protein (42kDa) and HSP 70 (75kDa)] were fused to a 6X His-tag and produced 
in E. coli, followed by affinity purification. These His-tagged proteins were mixed with 
the same ratio and used as the markers for the SDS-PAGE and western blotting, as 
described in section 2.5.5. A comparison of this lab-made protein marker and 
commercial protein marker is shown in figure 3.8.  
 
 
 
Figure 3.8 Comparison of lab-made protein marker with Bio-Rad standards  
5 µl of lab-made protein marker and 10 µl of Bio-Rad Precision plus protein dual Xtra 
standards were run on a 12% SDS-PAGE gel. The left picture shows the comparison of 
the size on SDS-PAGE stained by Coomassie blue; the picture in the middle shows the 
comparison on western blot, detected by monoclonal anti-polyHistidine-alkaline 
phosphatase antibody; the picture on the right is the Bio-Rad Precision plus protein 
dual Xtra standards.  
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3.3.2 Analysis of antibody expression and solubility in E. coli  
 
Protein expressed in pSANG vector was designed to secrete into the periplasmic space 
due to the presence of the PelB leader sequence at the 5’ end of the antibody scFv. To 
determine whether or not the antibodies were expressed in E. coli BL21(DE3)pRARE 
strain, the expressed antibody fragments were first examined by purifying the scFvs by 
Ni-NTA column from the total bacteria extracts under a denaturing condition with 8 M 
urea. After the His-tagged scFv protein was eluted from Ni-NTA column by decreasing 
the pH from 8.0 to 4.5, SDS-PAGE was used to analyse the purity and quantity (figure 
3.9, lane 7, 8 and 9). This shows that a dominated protein with expected scFv size was 
isolated and concentrated. Secondly, to determine whether the antibodies were soluble 
and correctly folded, the expressed antibody fragments were purified from the total cell 
extract under a native condition. 8 M urea was replaced by 50 mM NaH2PO4 in all the 
buffers but maintained the pH 8.0, and the scFv was eluted from the Ni-NTA column 
by increasing the imidazole concentration (figure 3.10, lane 7, 8 and 9). Finally, to 
examine whether the antibodies were secreted into the periplasmic space of E. coli, the 
periplasmic proteins were extracted by osmotic shock (see section 2.5.3), followed by 
Ni-NTA purification column (figure 3.11, lane 8 and 9). Figure 3.9-3.11 provides an 
example of the purification of the antibody pSANG-1-7, which was chosen to validate 
various purification strategies. The optimised purification conditions were then applied 
to other antibody fragments as shown in the appendix 4. 
 
 
Figure 3.9 Antibody 1-7 purified from total cell extract under the denaturing 
condition 
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Figure 3.10 Antibody 1-7 purified from total cell extract under the native 
condition 
 
 
 
Figure 3.11 Antibody 1-7 antibody purified from periplasmic fraction 
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The above figures (3.9-3.11) reveal the successful expression and purification of 
recombinant antibody fragment from E. coli. By comparing the uninduced (lane 2) and 
induced (lane 3) protein samples, it is shown that the recombinant antibody fragment 
was expressed at the expected size of 34 kDa upon IPTG induction. While large 
quantity of scFv was recovered under the denaturing condition (Figure 3.9, lane 7, 8 
and 9), only a small amount of the scFv was eluted under the native condition or from 
periplasm (figure 3.10 and 3.11), indicating that although recombinant scFv expressed 
in a large quantity, only a small fraction was soluble and secreted into periplasmic 
space. It was noticed that a number of contaminated proteins were also detected in the 
eluted samples (figure 3.10), which may reflect the inefficiency of IMAC purification 
under the native condition.  
 
To confirm the successful expression and secretion of soluble proteins, western 
blotting was applied and probed by monoclonal anti-polyHistidine-alkaline 
phosphatase antibody. Figure 3.12 shows the detection of the expressed scFv protein at 
34 kDa (lane 3) and eluted fractions (lane 7-10) from total cell extract purification 
under the native condition; while figure 3.13 shows the same protein expressed and 
purified from the periplasmic fraction. 
 
Four antibodies from library M325 (011, 1-1, 1-5 and 1-7) and three antibodies from 
library K530 (2-1, 2-2, 2-4) were expressed in pSANG vector and purified from both 
total cell extracts and periplasmic spaces, as described in chapter 2. It was shown that 
all seven antibody fragments were expressed, with an expected size of 33-34 kDa, 
which was again confirmed by western blotting with monoclonal anti-polyHistidine-
alkaline phosphatase antibody. These pictures also show that while more scFv protein 
was purified from total cell soluble fraction, secreted scFv protein recovered from the 
periplasmic fraction was much less. The antibodies 011, 1-1 and 2-1 did not show 
detectable scFv protein in the elution fractions when purified from periplasm by 
osmotic shock. See all SDS-PAGE and western blot pictures shown in the appendix 4. 
 
It has been estimated that an average yield of the scFv from the total soluble E. coli 
extract was about 100 – 500 µg from 200 ml of bacterial culture (i.e., 0.5-2.5 mg/L) 
after purification with Ni-NTA column followed by desalting with Centrifugal Filter 
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Units. However, the yield from the periplasm of E. coli is only 20 – 80 µg from 200 ml 
(i.e., 0.1-0.4 mg/L). Therefore, the total soluble cell fraction was used in the 
subsequent scFv purification. 
 
 
 
 
Figure 3.12 Antibody 1-7 purified from total cell extract under the native 
condition (western blot) 
 
 
 
Figure 3.13 Antibody 1-7 purified from periplasmic fraction (western blot) 
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3.3.3 Quick screening of antibodies expressed in pABEXT vector 
 
In order to rapidly screen antigen-binding antibodies, E. coli crude extract containing 
expressed antibodies without affinity purification was used directly in ELISA to test 
the binding to recombinant gp120 (as shown in figure 1.9). For this purpose, pABEXT 
vector was employed to express antibodies directly after one round of ribosome display 
in XL1-blue cells. In a preliminary study, total protein yield (purified under the 
denaturing condition) and soluble protein secretion (purified from the periplasm) were 
compared between pABEXT and pSANG vectors (figure 3.14, 3.15). Antibody 1-7 
exhibits lower protein yield when expressed in pABEXT vector (figure 3.14, lane 7, 8 
and 9), but comparable, if not more, soluble protein when it is expressed in pABEXT 
vector (figure 3.15, land 8 and 9). 
 
 
 
 
Figure 3.14 Comparison of protein yields between pABEXT and pSANG vectors 
Antibody 1-7 was expressed in pABEXT and pSANG vectors and purified from total 
cell extract under the denaturing condition. pABEXT vector showed less protein 
production than pSANG vector. 
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Figure 3.15 Comparison of soluble protein from periplasm between pABEXT and 
pSANG vectors 
Antibody 1-7 was expressed in pABEXT and pSANG vectors and purified from 
periplasm using Ni-NTA column. pABEXT vector showed no less secreted protein 
than pSANG vector. 
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In general, DNA fragments recovered from one round of ribosome display were 
digested with NcoI/NotI and ligated into pABEXT vector. E. coli XL1-blue was used 
to express the single-chain antibodies which contained the partial constant region 
(expected size of 44 – 46 kDa) (figure 2.6). 300 clones selected from library M325 and 
192 clones from library K530 were expressed in this method at 50 ml scale and the 
bacterially synthesised antibody fragments were extracted by osmotic shock and used 
directly for ELISA against recombinant gp120 and BSA (negative control). It has been 
shown that 20 clones from library M325 and 6 clones from library K530 demonstrated 
binding with varying degrees in the ELISA against gp120 derived from K530. Further 
test of these clones by ELISA in duplicate showed only 3 clones from library M325 
(I3, I4 and M5) were reliably showing the antigen binding. Figure 3.16 shows single-
chain antibody I3 was expressed at the expected size of 44 kDa (lane 3, 4 and 5). 
Compared with antibodies expressed in pSANG vector, antibodies I3, I4 and M5 
expressed in pABEXT vector were more viscous and difficult to analyse on gel 
electrophoresis. 
 
 
 
 
Figure 3.16 Single-chain antibody I3 expressed in pABEXT vector 
After one round of ribosome display, the selected antibodies were cloned into 
pABEXT vector directly and expressed in XL1-blue cells. An example of antibody I3 
expression and purification from both total cell extract and periplasm is shown here. 
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Subsequently, antibodies I3, I4 and M5 were sub-cloned and expressed in pSANG 
vector. These antibodies were again purified from both total cell extract and periplasm 
and analysed by SDS-PAGE and western blotting (figure 3.17, 3.18 and appendix 4). 
 
 
 
 
Figure 3.17 SDS-PAGE and western blot of antibody pSANG-I3 purified from 
total cell extract under the native condition 
 
 
 
Figure 3.18 SDS-PAGE and western blot of antibody pSANG-I3 purified from 
periplasmic fraction  
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3.3.4 Effect of the codon following the initiation codon AUG  
  
Some of the antibody fragments (such as pSANG-011 and pSANG 1-7) with distinct 
CDR sequences showed the expression at very low level (figure 3.19 and 3.20, left). 
Sequence studies also revealed that the codon following the initiation codon AUG was 
changed from GCC (Alanine) to GGC (Glycine). This could be the reason causing the 
poor protein expression (Bivona et al., 2010). In order to test this, the GGC (Glycine) 
was converted back to GCC (Alanine) by PCR. This has resulted in an improved 
protein level by 5-10 folds (Figure 3.19 and 3.20, right). 
 
 
  
 
Figure 3.19 Comparison of antibody pSANG-011 with one codon difference 
In left picture, an error codon of GGC (Glycine) was shown following the initiation 
codon AUG and the protein expression was very low after induction; in right picture, 
after correcting the error codon to GCC (Alanine), considerable protein expression was 
shown after induction. 
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Figure 3.20 Comparison of antibody pSANG-1-7 with one codon difference 
In left picture, an error codon of GGC (Glycine) was shown following the initiation 
codon AUG and the protein expression was very low after induction; in right picture, 
after correcting the error codon to GCC (Alanine), considerable protein expression was 
shown after induction. 
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3.3.5 Optimisation of protein expression  
 
To optimise protein expression, a number of conditions have been examined, including 
induction temperature and codon usage. Antibody induction was performed at 20°C for 
20 hours to minimise the formation of inclusion bodies and improve protein folding 
(Cabilly, 1989, Schein, 1993). However, it shows that protein solubility was not 
significantly improved when comparing to the protein expressed at 37°C for 3 hours 
(figure 3.21). 
 
 
 
Figure 3.21 Comparison of antibodies expression at different temperatures 
Antibody pSANG-011 was expressed at 37°C for 3 hours (left) and 20°C for 20 hours 
(right) separately. The improvement of protein yield and solubility was not significant. 
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The codon usage in the selected sequence (011, 1-1, 1-5, 1-7, I3, I4, M5, 2-1, 2-2 and 
2-4) were analysed to see if there was rare codon that was not covered by pRARE 
plasmid. pRARE encodes tRNA genes for rare codons Arginine (AGG, AGA), Glycine 
(GGA), Isoleucine (AUA), Leucine (CUA) and Proline (CCC) (Novy et al., 2001). 
However, a few codons that are also rare in E. coli were not included, such as Arginine 
(CGG, CGA) and Glycine (GGG). DNA sequencing shows that Arginine (CGG, CGA) 
and Glycine (GGG) presented in all the expressed proteins and consecutive rare codons 
presented in most sequences (1-1, 1-7, I3, I4, M5, 2-1, 2-2 and 2-4) as summarised in 
table 3.3. The presence of these rare codons may impede the translation of recombinant 
antibodies in E. coli (Kane, 1995). 
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Table 3.3 
Antibodies 
Rare codon  
CGA 
Rare codon  
CGG 
Rare codon  
GGG 
Consecutive 
rare codons 
011 2 3 6 0 
1-1 2 1 8 5 
1-5 2 3 6 0 
1-7 1 1 4 4 
I3 2 4 9 4 
I4 2 3 9 4 
M5 3 3 7 4 
2-1 2 1 8 1 
2-2 2 3 6 1 
2-4 2 3 6 1 
 
Table 3.3 Summary of rare codons excluded in pRARE plasmid and consecutive 
rare codons in expressed antibodies 
Rare codons Arginine (CGA and CGG) and Glycine (GGG) that are not included in 
pRARE plasmid are shown in all the expressed antibodies; consecutive rare codons 
such as CGG CGA, CGG ACG are shown in most of the antibody sequences. 
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3.4 Functional assays 
 
 
3.4.1 ELISA 
 
To examine the antibody specificity and binding, the 10 selected antibodies expressed 
in pSANG vector were tested in ELISA against recombinant gp120 generated from 
patient K530. The ELISA was performed on a 96-well Nunc plate. BSA was used as 
the negative control. Other negative controls include mAb-free wells. Bacterially 
expressed antibody fragments after purification from the total cell extract under the 
native condition at the final concentration of 25 µg/ml were incubated in each well 
(figure 3.22). As a comparison, antibodies purified from periplasm at the final 
concentration of 5 µg/ml were also included  (figure 3.23).  
 
 
 
Figure 3.22 Antibody binding to gp120 after purification from total cell extract 
under the native condition 
Antibodies purified from total cell extract showed binding activities to recombinant 
gp120 in ELISA (red columns), BSA was used as negative control (blue columns). 
MAb-free wells were also included as negative control (ctr).  
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While antibodies 1-7 and 2-2 showed highest binding affinity to gp120, other 
antibodies showed modest activity. However, they all bound specifically to gp120 
(figure 3.22). Binding to BSA was also observed from some samples (1-7, 2-2, I3, I4 
and M5), which may be caused by the use of BSA as blocking reagent in ribosome 
display. It was noticed that the signals of binding to gp120 were weaker when using 
the scFvs from the periplasm (figure 3.23) than that from total cell extract. The reduced 
binding observed with periplasmic scFvs was possibly due to a lower amount of 
antibody being recovered from the periplasm. Despite of less binding, the ELISA result 
using the antibodies from periplasm agrees with that from total cell extracts, 
confirming the binding activity of these antibodies. Based on figures 3.22 and 3.23, 
antibody 011, 1-7, 2-2, I3, I4 and M5 showed specific binding, while the other 4 
antibodies had less or no binding.  
 
 
   
 
Figure 3.23 Antibody binding to gp120 after purification from periplasmic 
fraction 
Antibodies purified from periplasmic fraction showed variable binding activities to 
recombinant gp120 in ELISA (red columns), BSA was used as negative control (blue 
columns). MAb-free wells were also included as negative control (ctr).  
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3.4.2 Neutralisation assay  
 
To examine the neutralising activity of the selected antibodies, TZM-bl cells were 
chosen for the assay. The antibodies purified from total cell extract under the native 
condition were used as they provided a higher amount of protein. In total, 10 selected 
antibodies from both libraries were incubated with K530 gp160-derived infectious 
chimeric molecular clones before assaying on TZM-bl cells. The neutralisation activity 
was measured by the reduction of Luciferase luminescence. Percentage of 
neutralisation is illustrated in figure 3.24. While three antibodies (1-5, 2-1 and 2-2) 
resulted in about 50% luminescence reduction in the assay, another three mAbs (1-1, 1-
7 and 2-4) displayed lower discrepancies compared to the control sample. This shows a 
modest neutralising activity, although they were not potent compared to plasma 
control.   
 
Thus, taking the ELISA data and neutralisation results together, clones 1-7 and 2-2 
showed best activities among 10 antibodies. Clones 1-1, 1-5, 2-1 and 2-4 showed 
modest function in both assays. The other four clones only showed binding in ELISA.  
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Figure 3.24 Percentage of neutralisation 
Chimeric molecular clones of HIV-1 gp160 derived from patient K530 were 
neutralised with 10 mAbs, at 50, 12 and 3 µg/ml respectively. Results were reported as 
percentage of neutralisation activity, relative to negative control with antibody-free 
wells. Each colour represents different antibody concentration, except plasma control 
was tested at 1:20, 1:80 and 1:320 dilutions, respectively. 
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Chapter 4 	  
 
Discussion 
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Within 30 years of discovery, HIV has become one of the most pathogenic viruses 
circulating in human beings and caused more than 25 million deaths. With the 
increased understanding of the virus replication and infection mechanism, significant 
progress has been made to block the virus entry, suppress the virus replication and thus 
delay the disease progression. Despite seven classes of ART that are currently used in 
the treatment of HIV infection (nucleoside RT inhibitors, nonnucleoside RT inhibitors, 
protease inhibitors, fusion inhibitors, entry inhibitors, HIV integrase strand transfer 
inhibitors and multi-class combination products) (FDA, 2010), about 10 million 
infected individuals are still unable to access or afford to these therapies. Therefore, a 
protective vaccine with a relative low cost is urgently needed. To overcome the 
extraordinary mutability and genetic diversity of HIV, an effective vaccine needs to 
induce both T cell cytotoxic activity to recognise and eliminate infected cells and 
neutralising antibodies to prevent further viral replication (Johnston and Fauci, 2008). 
Current vaccine candidates generally focus on eliciting cytotoxic T cell responses 
(Letvin, 2005), yet only a limited number of broadly neutralising mAbs have been 
produced (Burton and Weiss, 2010). It will facilitate a deep understanding of the nature 
of HIV-induced immune responses if more broadly neutralising mAbs could be 
produced by a simple and practical method. This study aimed at establishing such a 
method to generate human antibodies in vitro by combining ribosome display selection 
with DNA libraries made from patient’s blood. 
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4.1 Single-chain antibody library construction 
 
Construction of the antibody libraries in this project was designed to achieve the 
followings: (1) to cover all possible rearranged variable regions, (2) to identify 
antibody subclasses, and (3) to use as little blood sample as possible. Two libraries 
M325 and K530 have been constructed by PCR to contain 13 VL families (9 Vλ 
families and 4 Vκ families) and 8 VH families, covering all the functional variable 
genes listed in human gene database, V BASE (Sblattero and Bradbury, 1998). This is 
in contrast with previously reported method in which only γ1 (Fd region) and κ chains 
were amplified by PCR (Burton et al., 1991). DNA sequencing of the functional 
antibody candidates after one round of ribosome display revealed both lambda chains 
and kappa chains, despite that most reported anti-HIV-1 neutralising mAb sequences 
are limited to Vκ and VH chains. Unlike mouse immunoglobulin in which kappa 
chains predominant, both kappa and lambda chains are similarly presented in human 
(Das et al., 2008). Isolation of functional lambda chains from two independent libraries 
in this study indicates that all families of variable regions should be included in the 
library for a selection.  
 
The relationship between antibody function and its subclass was also investigated in 
this study. Previous research on neutralising mAbs was focusing on variable fragment 
or Fab, and the limited reports on antibody subclasses were restricted to IgG1 or IgG3 
(Burton et al., 1994, Buchacher et al., 1994). Although IgG1 and IgG3 subclasses are 
generally believed to be much more effective activators of the classical complement 
pathway, some studies suggested that IgG2 is also effective in activating complement 
when the epitope density is high (Michaelsen et al., 1991). Interestingly, subclasses 
IgG2 and IgG4 were found in several antibody candidates by this study, as well as 
IgG1 subclass that accounts for majority of the selected sequences. This agrees with 
the relative concentration of human immunoglobulin subclasses (IgG1>IgG2>IgG3 
=IgG4) (Meulenbroek and Zeijlemaker, 1996), whereas the fact that no IgG3 subclass 
was found could be probably due to the limited number of selected candidates. The 
role of immunoglobulin subclasses in HIV-1 neutralisation needs to be investigated 
further. In this study, we designed the library to genetically encode sequences that 
would permit the identification of the immunoglobulin subclass linked to its variable 
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heavy and light chains. We could readily differentiate human kappa and lambda light 
chains, IgG1, 2, 3 and 4 subclasses for the heavy chains without performing ELISA as 
previously described (Buchacher et al., 1994). Although not carried out in this study, 
the approach could be further applied to elucidate IgA and IgE, providing complete 
coverage of the immune repertoire.  
 
Importantly this study shows that large human antibody libraries could be constructed 
from 20 ml of blood, and possibly as little as 5 ml (this is achievable based on the 
amount of total RNA that was used in this study: to assemble a library requires 3 µg of 
total RNA; the amount of total RNA recovered approximate to 1 µg per ml blood). The 
libraries could be immediately used for selection of specific antibodies by in vitro 
ribosome display without the need for DNA cloning, thus maintaining the original 
library size and diversity.  
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4.2 Ribosome display selection 
 
Ribosome display was used in this study to isolate functional single-chain antibodies. 
This technology could be developed as an alternative method to previously common 
used methods such as EBV immortalisation (Buchacher et al., 1994, Corti et al., 2010) 
or phage display (Burton et al., 1991). Ribosome display is featured to allow efficient 
screening of a very large library without compromising the library size by 
transformation efficiency. The PCR amplified DNA library is readily selected against 
immobilised antigens before cloning and transforming into bacteria. Theoretically the 
library size is only restricted by the available ribosomes in the system. Ribosome 
display is also a time-saving method. One round of selection and recovery process can 
be accomplished in just one day, as no cell culture is involved. The initial ribosome 
display experiments using M325 library against gp120 derived from K530 employed 
three rounds of selection. This resulted in the recovery of an enriched population 
comprised of a single sequence for the scFv. This high degree of enrichment resulted in 
reduced diversity. Subsequently, it was decided to use a single round of ribosome 
display to enrich and recover more diverse candidates. 
 
The antibodies from both libraries were affinity selected against the same antigen: 
recombinant gp120 derived from patient K530. Interestingly, clones with identical 
CDR3 region were found from the two separate libraries, e.g. mAbs 011, 1-5 were 
from library M325 while mAbs 2-2, 2-4 from library K530 (see table 3.1). The 
recovery of the similar sequences with identical H-CDR3 suggests the success of the 
selection from the libraries by ribosome display technology. Antibody CDRs, in 
particular H-CDR3, play an important role in determining antibody specificity and 
affinity. The selection of the identical H-CDR3 from the two different libraries 
suggests that this H-CDR3 region is a dominating functional sequence from the two 
HIV patients. By comparing with existing neutralising mAbs, the H-CDR3 selected in 
this study is shorter (only 15 amino acids). It was generally shown that the existing 
neutralising mAbs have a protruding long H-CDR3, e.g., while 2F5 has 22 residues, 
both b12 and 4E10 with 18 amino acids (Zwick et al., 2004, Cardoso et al., 2005, 
Saphire et al., 2001). Recent study identified a 28-residue H-CDR3 in two other 
neutralising mAbs PG9 and PG16 (Pejchal et al., 2010). These H-CDR3s are usually 
longer than the average length of H-CDR3 in humans (13 residues), rabbits (11 to 12 
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residues) and mice (9-10 residues) (Wu and Cygler, 1993). In this study, only one long 
H-CDR3 (23 residues) was discovered from the patient libraries. 
 
These antibodies selected from both libraries have specific binding activity in ELISA 
(especially mAb 1-7 from library M325 and mAb 2-2 from library K530) and 
neutralising activity, confirming in vitro selection from patient libraries can rapidly 
produce functional antibodies. This also agrees with the result of preliminary patient 
serum screening: Serum M325 (CRF02_AG) neutralises clade B, C and CRF02_AG, 
and serum K530 (clade C) neutralises clade B, C, CRF01_AE and CRF02_AG. The 
current study shows that antibodies capable of neutralising a recombinant clade C 
antigen could be isolated from the libraries (see results 3.4.2). 
 
In the future, the selected antibodies could be tested with different HIV-1 subtypes to 
further characterise their neutralising activity. The breadth of antibody neutralisation is 
an important and interesting criterion of anti-HIV-1 neutralising antibodies. The 
current results encourage the continuation or extension of this work to generate a panel 
of different mAbs that would facilitate the discovery of potential candidates for 
therapeutic application.  
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4.3 Protein expression 
 
The expression and purification of recombinant antibodies has proved to be a 
bottleneck in this study and many factors that may affect protein expression were 
investigated. A total of 10 antibodies (7 from library M325 and 3 from library K530) 
were tested and the soluble fractions either from whole cell lysate or periplasmic space 
were analysed. The recombinant scFv proteins with the correct sizes were confirmed 
by protein gel electrophoresis and western blotting analysis. Both the T7 promoter 
based pSANG and the lac promoter based pABEXT vectors have shown utility in 
producing a large amount of recombinant scFv proteins within hours following 
induction. However, it was noticed that inclusion bodies formed, possibly due to the 
foreign nature of human immunoglobulins, and/or the high expression rate (Arbabi-
Ghahroudi et al., 2005). One possible route to recover functional proteins from 
inclusion bodies is by protein refolding. This was not attempted in this study due to 
time constraints and the requirement to reengineer the scFv without a signal peptide for 
cytoplasmic expression (Arbabi-Ghahroudi et al., 2005). Instead, efforts were made to 
identify the optimal conditions to produce soluble proteins in sufficient quantity for the 
subsequent studies. These included the use of different expression systems and 
optimising the expression conditions and codon usages, and protein recovery under 
different conditions. 
 
A side-by-side comparison has shown that protein purification from the total cell lysate 
generated more recombinant proteins than that from periplasmic space. However, 
purification from the periplasmic space generated a better purity. Usually, oxidised 
periplasmic space facilitates the folding and assembly of recombinant scFv, and the 
secreted proteins can be extracted by a simple osmotic shock procedure with less 
contaminants from bacterial proteins (Makrides, 1996). However, in practical, a 
substantial amount of recombinant scFv was not extracted, possibly due to the 
inefficiency of osmotic shock that causes the poor recovery of the scFv. Isolation of 
scFv proteins from the total cell lysate may overcome this problem, thus resulting in a 
better recovery of scFv proteins (figure 4.1). In this study, antibodies purified from 
both methods have been compared, showing scFv proteins purified from both methods 
preserved the correct folding and function.  
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Figure 4.1 Illustration of two purification methods 
Periplasmic protein was purified by osmotic shock, in which some scFv protein might 
stick to membranes and remain in the cell; Total cell purification generates more scFv 
protein by sonication, but it also showed more contaminating proteins. The cytoplasm 
is shown by the white circle, and the periplasmic space is shown by the blue area. 
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To further improve the scFv in the future, a screening procedure may be adapted, 
which has allowed identifying optimised conditions for protein expression in E. coli by 
a single experiment (Islam et al., 2007). In addition, more suitable host strains such as 
those to enhance the disulfide bond formation in the bacterial cytoplasm could be 
tested (Prinz et al., 1997), e.g., Rosetta-gami B strain. 
 
The plasmid pABEXT vector contains the lac promoter. Unlike the pSANG vector, it 
does not require T7 RNA polymerase to express proteins. Therefore selected 
antibodies could be expressed in normal hosts such as XL1-blue cells, without the need 
for the extra steps of transforming the plasmid into host bacteria BL21(DE3)pRARE. 
Compared with pSANG vector, antibodies expressed in pABEXT vector showed a 
lower protein yield, but similar or more soluble protein could be obtained after 
purification from the periplasm of E. coli. However, proteins expressed in pABEXT 
vector are more viscous and difficult to analyse by SDS-PAGE. As both of the plasmid 
systems have advantages and disadvantages, combined use of these two systems was 
adapted. In general, the pABEXT vector was used when a quick screening of 
antibodies was required while the pSANG system was used when a large-scale 
production of the candidates was needed (see results 3.3.3).  
 
It was shown that scFvs from the periplasmic extract without further purification could 
be directly used for functional test of the antibodies in ELISA. Thus this method was 
used to screen bacterial clones after ribosome display selection. This crude extract of 
scFv proteins may contain contaminated proteins/peptides that may affect the ELISA 
results. Therefore, potential candidates identified by this screening method were re-
tested by His-tag affinity purification. In addition, some antibodies may be truncated 
resulting in shorter polypeptides from the pABEXT system, thus causing false positive 
in ELISA. These antibodies were ruled out by western blotting when they failed to 
show correct size or by directly DNA sequencing. A number of mutations were also 
detected; these may have been produced during multiple amplifying and cloning steps. 
In future, this could be reduced by using higher fidelity polymerases. 
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The expression temperature was also examined in this study. Cultivation at a reduced 
temperatures is a well-known technique to reduce the aggregation of recombinant 
proteins and improve soluble protein yields (Weickert et al., 1996). It has shown 
effective in improving the solubility of many difficult proteins, such as bacterial 
luciferase (Vasina and Baneyx, 1997). Various strategies have been developed to 
express protein, especially toxic and unstable proteins at temperatures as low as 4°C 
(Ferrer et al., 2003, Mujacic et al., 1999). In a routine antibody production, the 
standard condition for protein expression was set to 20°C for 20 hours to reduce the 
cellular protein concentration and improve protein folding. However, in this study 
expression at a lower temperature for a longer period of time showed a similar yield of 
soluble proteins as that expressed at 37°C for 3 hours, indicated by SDS-PAGE results 
(figure 3.21).  
 
Codon usage has also been tested to increase the expression level of soluble proteins. 
As the second codon following the initiation codon AUG has been known to be crucial 
to protein expression, which is explained by the influence of the composing 
nucleotides on the structure of the ribosomal binding site (Looman et al., 1987). As 
Alanine located at the second position has shown to increase protein expression 
(Bivona et al., 2010), the Glycine at second position was replaced by Alanine in the 
clones 011 and 1-7. This has led to the improvement of protein expression by 5-10 
folds, agreeing with the previously published observation (Bivona et al., 2010). 
 
Rare codons were also detected across the sequences from the selected candidates due 
to the foreign nature of human immunoglobulin origin. To eliminate the rare codon 
bias in E. coli, the pRARE plasmid containing 6 rare codons was inserted into host 
bacteria BL21(DE3). This would facilitate expression of human scFvs in E. coli. 
However, there were 3 other rare codons Arginine (CGG, CGA) and Glycine (GGG) as 
well as consecutive rare codons (e.g. CGG CGA, CGG ACG) detected in the selected 
antibodies (table 3.3), which may cause the difficulty of producing soluble proteins. 
This problem could be reduced by using commercially available plasmids, such as 
pRARE2, which contain more rare codons. An alternative method could be to use 
Rosetta host strains such as Rosetta-origami B strains that are designed to enhance the 
expression of eukaryotic protein. 
	   	   	  113	  
4.4 Functional assays 
 
The selected antibody candidates have been demonstrated to be functional by both 
ELISA (figure 3.22, 3.23) and neutralisation assay (figure 3.24). Specific binding was 
observed in each antibody at 25 µg/ml against recombinant gp120 in ELISA (figure 
3.22). Furthermore, modest neutralising activity was observed from 6 antibodies (3 
from the library M325 and 3 from the library K530) at 50 µg/ml against recombinant 
gp160 (figure 3.24). The successful selection of functional antibody fragments by 
ribosome display technology from patient libraries suggests this could be an efficient 
route to rapidly generate specific antibodies in vitro. In addition, ribosome display is a 
powerful method for in vitro evolution of antibody fragments (He and Taussig, 2002), 
these selected antibodies can be further improved by ribosome display in a 
combination with mutagenesis. 
 
Antibody fragments 1-7 and 2-2 showed the highest activities in ELISA. The binding 
activity specific to the antigen suggests the correct folding of these proteins in bacteria. 
The results also suggest that the presence of 6XHis-tag and tri-FLAG-tag has no 
substantial effects on the function of the antibodies. A number of antibodies with the 
lower activity were also selected. These antibodies may be a background selection or 
may not fold correctly in E. coli, as they were selected in the format of antibody-
ribosome-mRNA complex produced in the rabbit reticulocyte lysate, a eukaryotic 
system. The functional antibodies purified from total cell or periplasm were 
functionally similar, showing either method could be used to produce the antibodies. 
However, in general, periplasmic space generates less scFvs but better folded 
fragments possibly due to the oxidizing environment and the presence of proteins that 
are important for folding and assembly of recombinant protein (Arbabi-Ghahroudi et 
al., 2005).  
 
Antibodies selected from the two libraries showed similar functions, suggesting the 
consistency of the method for the selection. It may also indicate these selected 
antibodies were functionally dominating molecules in the libraries. It would help to 
generate panels of different antibodies with more diversified sequences for a choice, 
especially for the therapy if more patient libraries could be generated in the future, and 
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selected with other defined antigens, such as trimeric gp120. Sequence studies show 
that the selected antibodies, despite very similar sequences and an identical CDR3 
region (e.g., 2-2 and 2-4), their antibody binding activities are not the same, suggesting 
their binding sites are not entirely determined by their CDR3 sequence. 
 
The neutralisation results suggest that antibodies with binding affinity to an antigen do 
not guarantee their function in neutralising the target in vivo. This has been observed 
by others working with HIV-1 neutralising mAbs (Burton et al., 1994), where they 
found that only a small part of the affinity selected antibodies (i.e., b12) showed potent 
neutralising activity even though other antibodies were also directed to the same 
binding site and had similar affinity to b12. Generally, antibodies can target many 
epitopes on HIV-1 Env protein, but potent neutralising activity could only be achieved 
by recognising the conserved epitopes that are essential for virus attaching and entry 
the cells (Wu et al., 2010). In this recent report, Wu and co-workers used molecular 
modelling to design the envelope protein to preserve only the CD4 binding site and 
eliminate extra antigenic regions of HIV-1. This “rational design of envelope”, which 
showed success in selecting antibody expressing B cells, could be used in our in vitro 
selection system in the future.  
 
It is of interest to note the PBMCs from donor K530 used to construct the antibody 
library were taken 3 years prior to PBMCs being taken for K530 gp120 isolation. 
During this 3-year period the HIV-1 virus surface proteins probably underwent some 
degree of genetic variations. The ability to recover antibodies that neutralise K530 
gp120 suggests these molecules were important in keeping the virus in check. It is 
possible that K530 gp120 emerged sooner or that the antibodies recognise a precursor 
to K530 gp120 that also recognise the current K530 gp120. The epitope may be a 
conserved functional epitope required by HIV-1. With the development of a method of 
capturing and accessing the antibody repertoire that in theory requires as little as 5 ml 
of blood, it should be possible to undertake longitudinal studies to follow the repertoire 
of the antibodies and the antigens. Such a study would facilitate a better understanding 
of HIV-1 escape and allow identification of broadly neutralising antibodies if 
recombinant antigen isolated from different timeline could be used, (e.g., recombinant 
gp120 from 0, 1, 3, 5 year of HIV-1 infection could be isolated from LTNP and used in 
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ribosome display, which could permit the production of broadly neutralising mAbs in 
the future). 
 
The caveats with the scFv approach adopted in comparison with naturally occurring 
serum antibodies are in lack of avidity, effector functions, and polyclonal specificities. 
The antibodies (IgG) in serum have two binding sites, secondly they also have Fc 
domains that can confer complement activation and/or binding to Fc receptors and are 
a cocktail of specificities. The recombinant scFvs are monovalent, lack effector 
functions and are mono-specific. However, if the neutralisation is purely a function of 
inhibiting virus attachment or entry, which is independent of effector function and does 
not require receptor cross-linking, then potent neutralising antibodies discovered in the 
scFv format would probably be very effective when engineered back to full-length IgG. 
Conversely it may be that more than one antibody specificity is required for 
neutralising a broad range of HIV-1 virus clades, thus the activity of polyclonal serum 
may not be readily reproduced by monoclonal antibodies as reported by (Scheid et al., 
2009, Mouquet et al., 2010). 	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4.5	  Summary	  
 
In summary, the project described in this thesis has established a novel approach for 
rapid selection of anti-HIV-1 antibody fragments by in vitro ribosome display of 
patient libraries. It could provide a powerful discovery tool for identification of 
therapeutic antibodies. The followings list the major results obtained: 
 
Two anti-HIV-1 antibody libraries (M325 and K530) have been constructed by PCR 
and can be used directly for ribosome display screening without the need for DNA 
cloning. It also shows that a library could be made using the blood sample of as little as 
20 ml; 
 
The eukaryotic ribosome display procedure has successfully led to the selection of 
functional human antibodies in vitro. Ten antibody candidates have been generated and 
their IgG subclasses have been identified by DNA sequencing.  
 
The selected recombinant antibodies have been expressed as scFv in E. coli, and a 
number of expression and purification conditions have been examined to generate 
soluble proteins.  
 
A rapid screening method has also been established using pABEXT vector, which 
facilitated E. coli expression and screening of individual clones for functional 
antibodies. 
 
The functions of the selected antibodies were confirmed in both ELISA and 
neutralisation assays. 
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4.6 Future studies 
 
In general, a procedure for the capturing and analysis of an immune repertoire that 
requires relatively small volumes of blood has been described. In the future, the 
approach will be refined and optimised to permit the construction of antibody libraries 
from as little as 5 ml of blood.  
 
In this study, we utilised monomeric gp120 as a capture antigen. The availability of 
trimeric gp120 and gp140 provides additional capture antigens.  
 
The scFvs isolated in this proof-of-concept study in future would be used to generate 
full-length IgG molecules produced in CHO cells using standard procedures. The 
recovered purified full-length IgG molecules would then be used in neutralising assays.  
  
With these refinements, it will be possible to undertake longitudinal studies capturing 
the repertoire of antibodies and antigens from sero-conversion through disease 
progression or lack of. 
 
These additional studies would permit a complete answer to the hypothesis that in a 
proportion of LTNP’s the pre-existence of antibodies that are able to cross neutralise 
viruses capable of evolving from those currently replicating ensures that virus load in 
held fully in check.  The effective control of virus replication by these antibodies 
prevents immune destruction and ensures the failure of disease to 
develop.  Understanding the factors controlling this balance between host and pathogen 
will inform the design of better therapeutic treatments and effective prophylactic 
vaccines against HIV. 
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Appendix 
 
1. Neutralising activity of patient sera 
 
Sera from two LTNPs (M325 and K530) were tested by Dr. Hanna Dreja (Centre for 
Infectious Disease, Institute of Cell and Molecular Science, Barts and The London, 
Queen Mary, University of London, UK). It was tested against different HIV-1 clades 
in TZM-bl assay (reciprocal dilution at which at least 60% of input virus was 
neutralised). Their neutralising activities are listed as following: 
 
Patient M325 (type CRF02_AG) 
Clade Titre 
B 80 
C 40 
CRF02_AG 160 
  
 
Patient K530 (type C) 
Clade Titre 
B 160 
C 160 
CRF01_AE 160 
CRF02_AG 1280 
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2. pABEXT vector sequence 
(Tac promoter is shaded in grey; Restriction digestion sites NcoI, NotI are underlined) 
 
CCGACACCATCGAATGGTGCAAAACCTTTCGCGGTATGGCATGATAGCGCCCGGA
AGAGAGTCAATTCAGGGTGGTGAATGTGAAACCAGTAACGTTATACGATGTCGCA
GAGTATGCCGGTGTCTCTTATCAGACCGTTTCCCGCGTGGTGAACCAGGCCAGCCA
CGTTTCTGCGAAAACGCGGGAAAAAGTGGAAGCGGCGATGGCGGAGCTGAATTAC
ATTCCCAACCGCGTGGCACAACAACTGGCGGGCAAACAGTCGTTGCTGATTGGCG
TTGCCACCTCCAGTCTGGCCCTGCACGCGCCGTCGCAAATTGTCGCGGCGATTAAA
TCTCGCGCCGATCAACTGGGTGCCAGCGTGGTGGTGTCGATGGTAGAACGAAGCG
GCGTCGAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCGCAACGCGTCAGTGG
GCTGATCATTAACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGCCT
GCACTAATGTTCCGGCGTTATTTCTTGATGTCTCTGACCAGACACCCATCAACAGT
ATTATTTTCTCCCATGAAGACGGTACGCGACTGGGCGTGGAGCATCTGGTCGCATT
GGGTCACCAGCAAATCGCGCTGTTAGCGGGCCCATTAAGTTCTGTCTCGGCGCGTC
TGCGTCTGGCTGGCTGGCATAAATATCTCACTCGCAATCAAATTCAGCCGATAGCG
GAACGGGAAGGCGACTGGAGTGCCATGTCCGGTTTTCAACAAACCATGCAAATGC
TGAATGAGGGCATCGTTCCCACTGCGATGCTGGTTGCCAACGATCAGATGGCGCT
GGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGCGCGTTGGTGCGGATATCTCG
GTAGTGGGATACGACGATACCGAAGACAGCTCATGTTATATCCCGCCGTTAACCA
CCATCAAACAGGATTTTCGCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCA
ACTCTCTCAGGGCCAGGCGGTGAAGGGCAATCAGCTGTTGCCCGTCTCACTGGTG
AAAAGAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGG
CCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTG
AGCGCAACGCAATTAATGTAAGTTAGCTCACTCATTAGGCACAATTCTCATGTTTG
ACAGCTTATCATCGACTGCACGGTGCACCAATGCTTCTGGCGTCAGGCAGCCATCG
GAAGCTGTGGTATGGCTGTGCAGGTCGTAAATCACTGCATAATTCGTGTCGCTCAA
GGCGCACTCCCGTTCTGGATAATGTTTTTTGCGCCGACATCATAACGGTTCTGGCA
AATATTCTGAAATGAGCTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAAT
TGTGAGCGGATAACAATTTCACACAGGAAACAGCCAGTCCGTTTAGGTGTTTTCAC
GAGCACTTCACCAACAAGGACCATAGCATATGAAATACCTGCTGCCGACCGCTGC
TGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCCATGGCCCAGGTGCAGCTGCAGG
CGGCCGCATCCGCACATCATCATCATCATCACAAGCTGGACTACAAAGACCATGA
CGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGACAAGTAATAA
AAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTA
CCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAA
GAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGC
AGCTTGGCTGTTTTGGCGGATGAGATAAGATTTTCAGCCTGATACAGATTAAATCA
GAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGG
TCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAG
TGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCCAGGCATCAAATAAAACGAAA
GGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCT
CCTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCC
GGAGGGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGCATCAAATTAAGCAG
AAGGCCATCCTGACGGATGGCCTTTTTGCGTTTCTACAAACTCTTTTGTTTATTTTT
CTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTC
AATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATT
CCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAA
GTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATC
TCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTCCCAATGATG
AGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCA
AGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCAC
CAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGC
TGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGA
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GGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCC
TTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACAC
CACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTA
CTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTG
CAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCT
GGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTA
AGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA
ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTG
TCAGACCAAGTTTACTCATATATACTTTAGATTGATTTACCCCGGTTGATAATCAG
AAAAGCCCCAAAAACAGGAAGATTGTATAAGCAAATATTTAAATTGTAAACGTTA
ATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAAT
AGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTT
GAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAAC
GTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCAC
CCAAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAA
AGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAA
GGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGT
CACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCG
TAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAAC
GTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCT
TGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCT
ACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAA
CTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTA
GGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCT
GTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAA
GACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCAC
ACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAG
CTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTA
AGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCC
TGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTG
TGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTT
TACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCC
TGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCA
GCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGA
TGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATATGGTGCAC
TCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACACTCCGCTATC
GCTACGTGACTGGGTCATGGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCG
CCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTC
CGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAG
CTGCGGTAAAGCTCATCAGCGTGGTCGTGCAGCGATTCACAGATGTCTGCCTGTTC
ATCCGCGTCCAGCTCGTTGAGTTTCTCCAGAAGCGTTAATGTCTGGCTTCTGATAA
AGCGGGCCATGTTAAGGGCGGTTTTTTCCTGTTTGGTCACTGATGCCTCCGTGTAA
GGGGGATTTCTGTTCATGGGGGTAATGATACCGATGAAACGAGAGAGGATGCTCA
CGATACGGGTTACTGATGATGAACATGCCCGGTTACTGGAACGTTGTGAGGGTAA
ACAACTGGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCAGGGTCAATGC
CAGCGCTTCGTTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATCCTGC
GATGCAGATCCGGAACATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTT
ACGAAACACGGAAACCGAAGACCATTCATGTTGTTGCTCAGGTCGCAGACGTTTT
GCAGCAGCAGTCGCTTCACGTTCGCTCGCGTATCGGTGATTCATTCTGCTAACCAG
TAAGGCAACCCCGCCAGCCTAGCCGGGTCCTCAACGACAGGAGCACGATCATGCG
CACCCGTGGCCAGGACCCAACGCTGCCCGAAATT 
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3. Nucleic acid and amino acid sequences of the selected scFvs 
(Link region and 6XHis-tag are shaded in grey)	  	  
>011 (33.46 kDa) 	  
atgggcgacatccagttgacccagtctccctcctcactgtctgcgtctgcaggagacaga 
 M  G  D  I  Q  L  T  Q  S  P  S  S  L  S  A  S  A  G  D  R  
gtcaccctcacttgtcgggcgagtcagggcattagcaatgatttagcccggcttcagcag 
 V  T  L  T  C  R  A  S  Q  G  I  S  N  D  L  A  R  L  Q  Q  
aaaccagggaaagcccctaagtccctgatctatgctgcatccagtttgcaaagtggggtc 
 K  P  G  K  A  P  K  S  L  I  Y  A  A  S  S  L  Q  S  G  V  
ccatcaaagttcagcggcagtggatctgagacagaattcactctcaccatcagcagcctg 
 P  S  K  F  S  G  S  G  S  E  T  E  F  T  L  T  I  S  S  L  
cagcctgatgatcctgcaacttactactgccaacagtacagtgcatcttcttcgacgttc 
 Q  P  D  D  P  A  T  Y  Y  C  Q  Q  Y  S  A  S  S  S  T  F  
ggccaagggaccaaggtggaaattaaacgaactgtggctgcaccatctgtcttcatcttc 
 G  Q  G  T  K  V  E  I  K  R  T  V  A  A  P  S  V  F  I  F  
ccgccatctgatgagcggctgaaatctggacagatcaccttgaaggagtctggtccggcg 
 P  P  S  D  E  R  L  K  S  G  Q  I  T  L  K  E  S  G  P  A  
ctggtgaagcccacacagacgctcacactggcctgcgccgtctctgggctctcgctcagc 
 L  V  K  P  T  Q  T  L  T  L  A  C  A  V  S  G  L  S  L  S  
acgagtggagtgcgagtgggttggctccgtcagcccccagggaaggccccggagtggcta 
 T  S  G  V  R  V  G  W  L  R  Q  P  P  G  K  A  P  E  W  L  
gcacgcattgattgggacgatgacaagttctacaacacttctctgaagaccaggctcacc 
 A  R  I  D  W  D  D  D  K  F  Y  N  T  S  L  K  T  R  L  T  
ctctccaaggacacctccaaaaatcaagtggttcttacaatgaccatcatggaccccgtg 
 L  S  K  D  T  S  K  N  Q  V  V  L  T  M  T  I  M  D  P  V  
gacacaggcacctattactgtgcgcgcctcgccgtggatacagttatggtacagggatat 
 D  T  G  T  Y  Y  C  A  R  L  A  V  D  T  V  M  V  Q  G  Y  
tttgacttgtggggccagggaatcatggtcaccgtctcctcagcctccaccaagggccca 
 F  D  L  W  G  Q  G  I  M  V  T  V  S  S  A  S  T  K  G  P  
tcggtcttccccctggcaccctcctccaagagcacctctgggggcacagcggccgcatcc 
 S  V  F  P  L  A  P  S  S  K  S  T  S  G  G  T  A  A  A  S  
gcacatcatcatcaccatcacaagctggactacaaagaccatgacggtgattataaagat 
 A  H  H  H  H  H  H  K  L  D  Y  K  D  H  D  G  D  Y  K  D  
catgacatcgattacaaggatgacgatgacaag 
 H  D  I  D  Y  K  D  D  D  D  K   
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>1-1 (34.16 kDa) 	  
atggccaattttatgctgactcagccccactctgtgtcggagtctccggggaagacggta 
 M  A  N  F  M  L  T  Q  P  H  S  V  S  E  S  P  G  K  T  V  
accatctcctgcacccgcaccagtggcagtattgccagcaagtatgtgcagtggtaccaa 
 T  I  S  C  T  R  T  S  G  S  I  A  S  K  Y  V  Q  W  Y  Q  
cagcgcccgggcagtgcccccacaactgtgatgtttgaggatagtcaaagaccctctggg 
 Q  R  P  G  S  A  P  T  T  V  M  F  E  D  S  Q  R  P  S  G  
gtccctgatcggttctctggctccatcgacagctcctccaattctgccttcctcaccatc 
 V  P  D  R  F  S  G  S  I  D  S  S  S  N  S  A  F  L  T  I  
gctggactgcagcctgaggacgaggctgactactattgtcagtcttatgataacagaaat 
 A  G  L  Q  P  E  D  E  A  D  Y  Y  C  Q  S  Y  D  N  R  N  
cagatcttcggcggagggaccaagttgaccgtcctaggtcagcccaaggctgccccctcg 
 Q  I  F  G  G  G  T  K  L  T  V  L  G  Q  P  K  A  A  P  S  
gtcactctgttcccaccctcctctgaggagctccaagccgaggtgcagctgttggagacc 
 V  T  L  F  P  P  S  S  E  E  L  Q  A  E  V  Q  L  L  E  T  
gggggaggcttagttcagcctggggggtccctgagactctcctgtgcagcctctagattc 
 G  G  G  L  V  Q  P  G  G  S  L  R  L  S  C  A  A  S  R  F  
agcttcaagaactactggatgcagtgggtccgccaacctccagggaaggggctggtgtgg 
 S  F  K  N  Y  W  M  Q  W  V  R  Q  P  P  G  K  G  L  V  W  
gtctcacgtatcaacaacgacggaaatcagaaaagatacgcggacggcgtgaagggccga 
 V  S  R  I  N  N  D  G  N  Q  K  R  Y  A  D  G  V  K  G  R  
ttcaccatctccagagacaacgccaagaacacgctgtccctgcaaatggacagtctacga 
 F  T  I  S  R  D  N  A  K  N  T  L  S  L  Q  M  D  S  L  R  
gccgaggacacggcggtgtattactgtgtcagacaatcccttgataattatgcttaccac 
 A  E  D  T  A  V  Y  Y  C  V  R  Q  S  L  D  N  Y  A  Y  H  
ttagactactggggccagggaaccctggtcaccgtctcctcagcctccaccaagggccca 
 L  D  Y  W  G  Q  G  T  L  V  T  V  S  S  A  S  T  K  G  P  
tcggtcttccccctggcgccctgctccaggagcacctccgagagcacagcggccgcatcc 
 S  V  F  P  L  A  P  C  S  R  S  T  S  E  S  T  A  A  A  S  
gcacatcatcatcaccatcacaagctggactacaaagaccatgacgtgattataaagatc 
 A  H  H  H  H  H  H  K  L  D  Y  K  D  H  D  V  I  I  K  I  
atgacatcgattacaaggatgacgatgacagta 
 M  T  S  I  T  R  M  T  M  T  V   	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>1-5 (33.45 kDa) 	  
atggccgacatccagttgacccagtctccctcctcactgtctgcgtctgcaggagacaga 
 M  A  D  I  Q  L  T  Q  S  P  S  S  L  S  A  S  A  G  D  R  
gtcaccctcacttgtcgggcgagtcagggcattagcaatgatttagcccggtttcagcag 
 V  T  L  T  C  R  A  S  Q  G  I  S  N  D  L  A  R  F  Q  Q  
aaaccagggaaagcccctaagtccctgatctatgctgcatccagtttgcaaagtggggtc 
 K  P  G  K  A  P  K  S  L  I  Y  A  A  S  S  L  Q  S  G  V  
ccatcaaagttcagcggcagtggatctgagacagaattcactctcaccatcagcagcctg 
 P  S  K  F  S  G  S  G  S  E  T  E  F  T  L  T  I  S  S  L  
cagcctgatgatcctgcaacttactactgccaacagtacagtgcatcttcttcgacgttc 
 Q  P  D  D  P  A  T  Y  Y  C  Q  Q  Y  S  A  S  S  S  T  F  
ggccaagggaccaaggtggaaattaaacgaactgtggctgcaccatctgtcttcatcttc 
 G  Q  G  T  K  V  E  I  K  R  T  V  A  A  P  S  V  F  I  F  
ccgccatctgatgagcggctgaaatctggacagatcgccttgaaggagtctggtccggcg 
 P  P  S  D  E  R  L  K  S  G  Q  I  A  L  K  E  S  G  P  A  
ctggtgaagcccacacagacgctcacactggcctgcgccgtctctgggctctcgctcagc 
 L  V  K  P  T  Q  T  L  T  L  A  C  A  V  S  G  L  S  L  S  
acgagtggagtgcgagtgggttggctccgtcagcccccagggaaggccccggagtggcta 
 T  S  G  V  R  V  G  W  L  R  Q  P  P  G  K  A  P  E  W  L  
gcacgcattgattgggacgatgacaagttctacaacacttctctgaagaccaggctcacc 
 A  R  I  D  W  D  D  D  K  F  Y  N  T  S  L  K  T  R  L  T  
ctctccaaggacacctccaaaaatcaagtggttcttacaatgaccaacatggaccccgtg 
 L  S  K  D  T  S  K  N  Q  V  V  L  T  M  T  N  M  D  P  V  
gacacaggcacctattactgtgcgcgcctcgccgtggatacagttatggtacagggatat 
 D  T  G  T  Y  Y  C  A  R  L  A  V  D  T  V  M  V  Q  G  Y  
tttgacttgtggggccagggaatcatggtcaccgtctcctcagcctccaccaagggccca 
 F  D  L  W  G  Q  G  I  M  V  T  V  S  S  A  S  T  K  G  P  
tcggtcttccccctggcgccctcctccaagggcacctctgggggcacagcggccgcatcc 
 S  V  F  P  L  A  P  S  S  K  G  T  S  G  G  T  A  A  A  S  
gcacatcatcatcaccatcacaagctggactacaaagaccatgacggtgattataaagat 
 A  H  H  H  H  H  H  K  L  D  Y  K  D  H  D  G  D  Y  K  D  
catgacatcgattacaaggatgacgatgacaag 
 H  D  I  D  Y  K  D  D  D  D  K  
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>1-7 (34.64 kDa) 	  
atggccaattttatgctgactcagccccgctctgtgtcggaatctccggggaggacggtg 
 M  A  N  F  M  L  T  Q  P  R  S  V  S  E  S  P  G  R  T  V  
atcatctcctgcacccgcagcactggcaccattgccgccaactatgtgcagtggtaccag 
 I  I  S  C  T  R  S  T  G  T  I  A  A  N  Y  V  Q  W  Y  Q  
cagcgcccgggcaattcccccaccactgtaatctttgaggataaccaaagaccctctggg 
 Q  R  P  G  N  S  P  T  T  V  I  F  E  D  N  Q  R  P  S  G  
gtccctgatcggttctctggctccatcgacagctcctccaactctgcctccctcaccatc 
 V  P  D  R  F  S  G  S  I  D  S  S  S  N  S  A  S  L  T  I  
cctagactgaagactgaggacgaggctgactactactgtcagtcttatgaagccagcagt 
 P  R  L  K  T  E  D  E  A  D  Y  Y  C  Q  S  Y  E  A  S  S  
catgagtgggtgctcggcggcgggaccaagctgaccgtcctaggtcagcccaaggctgcc 
 H  E  W  V  L  G  G  G  T  K  L  T  V  L  G  Q  P  K  A  A  
ccctcggtcactctgttcccaccctcctctgaggagctccaagcccaggtacagctgcag 
 P  S  V  T  L  F  P  P  S  S  E  E  L  Q  A  Q  V  Q  L  Q  
cagtcaggtccaggagtggtgaagccctcgcagaccctctcactcacctgtgccatctcc 
 Q  S  G  P  G  V  V  K  P  S  Q  T  L  S  L  T  C  A  I  S  
ggcgacagtgtctctagcgacagtggtgcttggaactggatcaggcagtccccatcggga 
 G  D  S  V  S  S  D  S  G  A  W  N  W  I  R  Q  S  P  S  G  
ggccttgagtggctgggaaggacatactacaggtccaagtggtccaagtggtataatgat 
 G  L  E  W  L  G  R  T  Y  Y  R  S  K  W  S  K  W  Y  N  D  
tatgcagtatctctgaaaagtcgaataaccattaatccagacacatccaagaaccagtcc 
 Y  A  V  S  L  K  S  R  I  T  I  N  P  D  T  S  K  N  Q  S  
tccctgcacctgaactctgtgactcccgaggacgcggctgtgtattactgtgcaagagac 
 S  L  H  L  N  S  V  T  P  E  D  A  A  V  Y  Y  C  A  R  D  
gaggtaactggaactggtgttttggactactggggccagggaaccctggtcaccgtctcc 
 E  V  T  G  T  G  V  L  D  Y  W  G  Q  G  T  L  V  T  V  S  
tcagcctccaccaagggcccatcggtcttccccctggcaccctcctccgagagcacctct 
 S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  E  S  T  S  
gggggcacagcggccgcatccccacatcatcatcaccatcacaagctggactacaaagac 
 G  G  T  A  A  A  S  P  H  H  H  H  H  H  K  L  D  Y  K  D  
catgacggtgattataaagatcatgacatcgattacaaggatgacgatgacaag 
 H  D  G  D  Y  K  D  H  D  I  D  Y  K  D  D  D  D  K  
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>2-1 (34.19 kDa) 
 
atggccaattttatgctgactcagccccactctgtgtcggagtctccggggaagacggta 
 M  A  N  F  M  L  T  Q  P  H  S  V  S  E  S  P  G  K  T  V  
accatctcctgcacccgcaccagtggcagtattgccagcaagtatgtgcagtggtaccaa 
 T  I  S  C  T  R  T  S  G  S  I  A  S  K  Y  V  Q  W  Y  Q  
cagcgcccgggcagtgcccccacaactgtgatgtttgaggatagtcaaagaccctctggg 
 Q  R  P  G  S  A  P  T  T  V  M  F  E  D  S  Q  R  P  S  G  
gtccctgatcggttctctggctccatcgacagctcctccaattctgccttcctcaccatc 
 V  P  D  R  F  S  G  S  I  D  S  S  S  N  S  A  F  L  T  I  
tctggactgcagcctgaggacgaggctggctactattgtcagtcttatgataacagaaat 
 S  G  L  Q  P  E  D  E  A  G  Y  Y  C  Q  S  Y  D  N  R  N  
cagatcttcggcggagggaccaagttgaccgtcctaggtcagcccaaggctgccccctcg 
 Q  I  F  G  G  G  T  K  L  T  V  L  G  Q  P  K  A  A  P  S  
gtcactctgttcccaccctcctctgaggagctccaagccgaggtgcagctgttggagacc 
 V  T  L  F  P  P  S  S  E  E  L  Q  A  E  V  Q  L  L  E  T  
gggggaggcttagttcagcctggggggtccctgagactctcctgtgcagcctctagattc 
 G  G  G  L  V  Q  P  G  G  S  L  R  L  S  C  A  A  S  R  F  
agcttcaagagctactggatgcagtgggtccgccaacctccagggaaggggctggtgtgg 
 S  F  K  S  Y  W  M  Q  W  V  R  Q  P  P  G  K  G  L  V  W  
gtctcacatatcaacaacgacggaaatcagaaaagatacgcggacggcgtgaagggccga 
 V  S  H  I  N  N  D  G  N  Q  K  R  Y  A  D  G  V  K  G  R  
ttcaccatctccagagacaacgccaagaacacgctgtccctgcaaatggacagtctacga 
 F  T  I  S  R  D  N  A  K  N  T  L  S  L  Q  M  D  S  L  R  
gccgaggacacggcggtgtattactgtgtcagacaatcccttgataattatgcttaccac 
 A  E  D  T  A  V  Y  Y  C  V  R  Q  S  L  D  N  Y  A  Y  H  
ttagactactggggccagggaaccctggtcaccgtctcctcagcctccaccaagggccca 
 L  D  Y  W  G  Q  G  T  L  V  T  V  S  S  A  S  T  K  G  P  
tcggtcttccccctggcgccctgctccaggagcacctccgagagcacagcggccgcatcc 
 S  V  F  P  L  A  P  C  S  R  S  T  S  E  S  T  A  A  A  S  
gcccatcatcatcaccatcacaagctggactacaaagaccatgacggtgattataaagat 
 A  H  H  H  H  H  H  K  L  D  Y  K  D  H  D  G  D  Y  K  D  
catgacatcgattacaaggatgacgatgacaag 
 H  D  I  D  Y  K  D  D  D  D  K   	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>2-2 (33.44 kDa) 	  
atggccgacatccaggtgacccagtctccctcctcactgtctgcgtctgcaggagacaga 
 M  A  D  I  Q  V  T  Q  S  P  S  S  L  S  A  S  A  G  D  R  
gtcaccctcactcgtcgggcgagtcagggcattagcaatgatttagcccggtttcagcag 
 V  T  L  T  R  R  A  S  Q  G  I  S  N  D  L  A  R  F  Q  Q  
aaaccagggaaagcccctaagtccctgatctatgctgcatccagtttgcaaagtggggtc 
 K  P  G  K  A  P  K  S  L  I  Y  A  A  S  S  L  Q  S  G  V  
ccatcaaagtccagcggcagtggatctgagacagaattcactctcaccatcagcagcctg 
 P  S  K  S  S  G  S  G  S  E  T  E  F  T  L  T  I  S  S  L  
cagcctgatgatccagcaacttactactgccaacagtacagtgcatcttcttcgacgttc 
 Q  P  D  D  P  A  T  Y  Y  C  Q  Q  Y  S  A  S  S  S  T  F  
ggccaagggaccaaggtggaaattaaacgaactgtggctgcaccatctgtcttcatcttc 
 G  Q  G  T  K  V  E  I  K  R  T  V  A  A  P  S  V  F  I  F  
ccgccatctgatgagcggctgaaatctggacagatcaccttgaaggagtctggtccggcg 
 P  P  S  D  E  R  L  K  S  G  Q  I  T  L  K  E  S  G  P  A  
ctggtgaagcccacacagacgctcacactggcctgcgccgtctctgggccctcgctcagc 
 L  V  K  P  T  Q  T  L  T  L  A  C  A  V  S  G  P  S  L  S  
acgagtggagtgcgagtgggttggctccgtcagcccccagggaaggccccggagtggcta 
 T  S  G  V  R  V  G  W  L  R  Q  P  P  G  K  A  P  E  W  L  
gcacgcattgattgggacgatgacaagttctacaacacttctctgaagaccaggctcacc 
 A  R  I  D  W  D  D  D  K  F  Y  N  T  S  L  K  T  R  L  T  
ctctccaaggacgcctccaaaaatcaagtggttcttacaatgaccgacatggaccccgtg 
 L  S  K  D  A  S  K  N  Q  V  V  L  T  M  T  D  M  D  P  V  
gacacaggcacctattactgtgcgcgcctcgccgtggatacagttatggtacagggatat 
 D  T  G  T  Y  Y  C  A  R  L  A  V  D  T  V  M  V  Q  G  Y  
tttgacttgtggggccagggaatcatggtcaccgtctcctcagcctccaccaagggccca 
 F  D  L  W  G  Q  G  I  M  V  T  V  S  S  A  S  T  K  G  P  
tcggtcttccccctggcaccctcctccaagagcacctctgggggcacagcggccgcatcc 
 S  V  F  P  L  A  P  S  S  K  S  T  S  G  G  T  A  A  A  S  
gcacatcatcatcaccatcacaagctggactacaaagaccatgacggtgattataaagat 
 A  H  H  H  H  H  H  K  L  D  Y  K  D  H  D  G  D  Y  K  D  
catgacatcgattacaaggatgacgatgacaag 
 H  D  I  D  Y  K  D  D  D  D  K   
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>2-4 (33.48 kDa)  	  
atggccgacattcagttgacccagtctccctcctcactgtctgcgtctgcaggagacaga 
 M  A  D  I  Q  L  T  Q  S  P  S  S  L  S  A  S  A  G  D  R  
gtcaccctcacttgtcgggcgagtcagggcattagcaatgatttagcccggtttcagcag 
 V  T  L  T  C  R  A  S  Q  G  I  S  N  D  L  A  R  F  Q  Q  
aaaccagggaaagcccctaagtccctgatctatgctgcatccagtttgcaaagtggggtc 
 K  P  G  K  A  P  K  S  L  I  Y  A  A  S  S  L  Q  S  G  V  
ccatcaaagttcagcggcagtggatctgagacagaattcactctcaccatcagcagcctg 
 P  S  K  F  S  G  S  G  S  E  T  E  F  T  L  T  I  S  S  L  
cagcctgatgatcctgcaacttactactgccaacagtacagtgcatcttcttcgacgttc 
 Q  P  D  D  P  A  T  Y  Y  C  Q  Q  Y  S  A  S  S  S  T  F  
ggccaagggaccaaggtggaaattaaacgaactgtggctgcaccatctgtcttcatcttc 
 G  Q  G  T  K  V  E  I  K  R  T  V  A  A  P  S  V  F  I  F  
ccgccatctgatgagcggctgaaatctggacagatcaccttgaaggagtctggtccggcg 
 P  P  S  D  E  R  L  K  S  G  Q  I  T  L  K  E  S  G  P  A  
ctggtgaggcccacacagacgctcacactggcctgcgccgtctctgggctctcgctcagc 
 L  V  R  P  T  Q  T  L  T  L  A  C  A  V  S  G  L  S  L  S  
acgagtggagtgcgagtgggttggctccgtcagcccccagggaaggccccggagtggcta 
 T  S  G  V  R  V  G  W  L  R  Q  P  P  G  K  A  P  E  W  L  
gcacgcattgattgggacgatgacaagttctacaacacttctctgaagaccaggctcacc 
 A  R  I  D  W  D  D  D  K  F  Y  N  T  S  L  K  T  R  L  T  
ctctccgaggacacctccaaaaatcaagtggttcttacaatgaccaacatggaccccgtg 
 L  S  E  D  T  S  K  N  Q  V  V  L  T  M  T  N  M  D  P  V  
ggcacaggcacctattactgtgcgcgcctcgccgtggatacagttatggtacagggatat 
 G  T  G  T  Y  Y  C  A  R  L  A  V  D  T  V  M  V  Q  G  Y  
tttgacttgtggggccagggaatcatggtcaccgtctcctcagcctccaccaagggccca 
 F  D  L  W  G  Q  G  I  M  V  T  V  S  S  A  S  T  K  G  P  
tcggtcttccccctggcaccctcctccaagagcacctctgggggcacagcggccgcatcc 
 S  V  F  P  L  A  P  S  S  K  S  T  S  G  G  T  A  A  A  S  
gcacatcatcatcaccatcacaagctggactacaaagaccatgacggtgattataaagat 
 A  H  H  H  H  H  H  K  L  D  Y  K  D  H  D  G  D  Y  K  D  
catgacatcgattacaaggatgacgatgacaag 
 H  D  I  D  Y  K  D  D  D  D  K   	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>I3 (33.5 kDa) 	  
atggccgacatccgggtgacccagtctccaggcaccctgtctttatcaccaggggaagga 
 M  A  D  I  R  V  T  Q  S  P  G  T  L  S  L  S  P  G  E  G  
gccaccctctcctgcagggccagtgagactgttaggttcaattacgtcgcctggtatcag 
 A  T  L  S  C  R  A  S  E  T  V  R  F  N  Y  V  A  W  Y  Q  
cagaaacctggccagcctcccaggctcctcatctatggtgcgtccaagagggccactggc 
 Q  K  P  G  Q  P  P  R  L  L  I  Y  G  A  S  K  R  A  T  G  
atcccagacaggtttagtggcagtgggtctgggaccgacttcgctctcaccatcagcaga 
 I  P  D  R  F  S  G  S  G  S  G  T  D  F  A  L  T  I  S  R  
ctagagcctgaagattttgcagtctattactgtcagcggtatggtagctcacctcgggcg 
 L  E  P  E  D  F  A  V  Y  Y  C  Q  R  Y  G  S  S  P  R  A  
ttcggcccagggaccaaggtggaattcaaacgaactgtggctgcaccatccgtcttcatc 
 F  G  P  G  T  K  V  E  F  K  R  T  V  A  A  P  S  V  F  I  
ttcccgccatctgatgagcagttgaaatctggacaggtccagcttgtacagtctggggct 
 F  P  P  S  D  E  Q  L  K  S  G  Q  V  Q  L  V  Q  S  G  A  
gaggtgaagaagcctgggtcctcggtgaaggtctcctgcaagacttctggaggcaccttc 
 E  V  K  K  P  G  S  S  V  K  V  S  C  K  T  S  G  G  T  F  
agcagctatgctatcagttgggtgcgacaggcccccggacaggggcttgaatgggtggga 
 S  S  Y  A  I  S  W  V  R  Q  A  P  G  Q  G  L  E  W  V  G  
gggatcatccctccctctggcacaacaaactacgcacagaagatccggggcagagtcacg 
 G  I  I  P  P  S  G  T  T  N  Y  A  Q  K  I  R  G  R  V  T  
attaccgcggacgaatccacgagcacagcctacatggagctgagcagcctgatatctgag 
 I  T  A  D  E  S  T  S  T  A  Y  M  E  L  S  S  L  I  S  E  
gacacggccgtgtattactgtgcgagagatcacgtggatacacctatgggccttgactat 
 D  T  A  V  Y  Y  C  A  R  D  H  V  D  T  P  M  G  L  D  Y  
tggagccagggaaccctggtcaccgtctcctcagcctccaccaagggcccatcggtcttc 
 W  S  Q  G  T  L  V  T  V  S  S  A  S  T  K  G  P  S  V  F  
cccctggcaccctcctccaagagcacctctgggggcacagcggccgcatccgcacatcat 
 P  L  A  P  S  S  K  S  T  S  G  G  T  A  A  A  S  A  H  H  
catcaccatcacaagctggactacaaagaccatgacggtgattataaagatcatgacatc 
 H  H  H  H  K  L  D  Y  K  D  H  D  G  D  Y  K  D  H  D  I  
gattacaagatgacgatgacagtaataaagctt 
 D  Y  K  M  T  M  T  V  I  K  L   
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>I4 (33.32 kDa) 	  
atggccgacatccaggtgacccagtctccaggcaccctgtctttatcaccaggggaagga 
 M  A  D  I  Q  V  T  Q  S  P  G  T  L  S  L  S  P  G  E  G  
gccaccctctcctgcagggccagtgagactgttaggttcaattacgtcgcctggtatcag 
 A  T  L  S  C  R  A  S  E  T  V  R  F  N  Y  V  A  W  Y  Q  
cagaaacctggccagcctcccaggctcctcatctatggtgcgtccaagagggccactggc 
 Q  K  P  G  Q  P  P  R  L  L  I  Y  G  A  S  K  R  A  T  G  
atcccagacaggtctagtggcagtgggtctgggaccgacttcgctctcaccatcagcaga 
 I  P  D  R  S  S  G  S  G  S  G  T  D  F  A  L  T  I  S  R  
ctagagcctgaagattttgcagtctattactgtcagcggtatggtagctcacctcgggcg 
 L  E  P  E  D  F  A  V  Y  Y  C  Q  R  Y  G  S  S  P  R  A  
ttcggcctagggaccaaggtggaattcaaacgaactgtggctgcaccatctgtcttcatc 
 F  G  L  G  T  K  V  E  F  K  R  T  V  A  A  P  S  V  F  I  
ttcccgccatctgatgagcagttgaaatctggacaggtccagcttgtacagtctggggct 
 F  P  P  S  D  E  Q  L  K  S  G  Q  V  Q  L  V  Q  S  G  A  
gaggtgaagaagcctgggtcctcggtgaaggtctcctgcaagacttctggaggcaccttc 
 E  V  K  K  P  G  S  S  V  K  V  S  C  K  T  S  G  G  T  F  
agcagctatgctatcagttgggtgcgacaggcctccggacaggggcttgaatggatggga 
 S  S  Y  A  I  S  W  V  R  Q  A  S  G  Q  G  L  E  W  M  G  
gggatcatccctccctctggcacaacaaactacgcacagaagatccggggcagagtcacg 
 G  I  I  P  P  S  G  T  T  N  Y  A  Q  K  I  R  G  R  V  T  
attaccgcggacgaatccacgagcacagcctacatggagctgagcagcctgatatctgag 
 I  T  A  D  E  S  T  S  T  A  Y  M  E  L  S  S  L  I  S  E  
gacacggccgtgtattactgtgcgagagatcacgtggatacacctatgggccttgactat 
 D  T  A  V  Y  Y  C  A  R  D  H  V  D  T  P  M  G  L  D  Y  
tggagccagggaaccctggtcaccgtctcctcagcctccaccaagggcccatcggtcttc 
 W  S  Q  G  T  L  V  T  V  S  S  A  S  T  K  G  P  S  V  F  
cccctggcaccctcctccaagagcacctctgggggcacagcggccgcatccgcacatcat 
 P  L  A  P  S  S  K  S  T  S  G  G  T  A  A  A  S  A  H  H  
catcaccatcacaagctggactacaagaccatgacggtgattataaagatcatgacatcg 
 H  H  H  H  K  L  D  Y  K  T  M  T  V  I  I  K  I  M  T  S  
attacaaggatgacgatgacagtaataaagctt 
 I  T  R  M  T  M  T  V  I  K  L   
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>M5 (34.94 kDa) 	  
atggccaattttatgctgactcagcccccctcagtgtccgtgtccccaggacagacagcc 
 M  A  N  F  M  L  T  Q  P  P  S  V  S  V  S  P  G  Q  T  A  
agcatcacctgctctggagataaattgggggataaatatgcttgttggtatcagcagaag 
 S  I  T  C  S  G  D  K  L  G  D  K  Y  A  C  W  Y  Q  Q  K  
ccaggccagtcccctgtcctggtcatccatcaagataacaagcggccctcagggatccct 
 P  G  Q  S  P  V  L  V  I  H  Q  D  N  K  R  P  S  G  I  P  
gagcgattctctggctccaattctgggaacacagccactctgaccatcagcgggacccag 
 E  R  F  S  G  S  N  S  G  N  T  A  T  L  T  I  S  G  T  Q  
gctatggatgaggctgactactactgtcaggcgtgggacagcagcactgtggtatccggc 
 A  M  D  E  A  D  Y  Y  C  Q  A  W  D  S  S  T  V  V  S  G  
ggagggaccaagctgaccgtcctaggtcagcccaaggctgccccctcggccactctgttc 
 G  G  T  K  L  T  V  L  G  Q  P  K  A  A  P  S  A  T  L  F  
ccgccctcctctgaggagctccaagcccaggtgcagctgcaggagtcgggcccaggactg 
 P  P  S  S  E  E  L  Q  A  Q  V  Q  L  Q  E  S  G  P  G  L  
gtgaagccctccgagaccctgaccctcaactgctctgtctctggtggctccataaataga 
 V  K  P  S  E  T  L  T  L  N  C  S  V  S  G  G  S  I  N  R  
tattactggagttggatccggcagtccccggggaatggactagagtggattggctacgtc 
 Y  Y  W  S  W  I  R  Q  S  P  G  N  G  L  E  W  I  G  Y  V  
tattctaacggaaataccaattacaacccctccctcgagagtcgagtcaccatctcagtc 
 Y  S  N  G  N  T  N  Y  N  P  S  L  E  S  R  V  T  I  S  V  
gacgtgtccaggaaccagttttccctgcagttgacctctgtgacggccgcagacacggcc 
 D  V  S  R  N  Q  F  S  L  Q  L  T  S  V  T  A  A  D  T  A  
ctatattactgtgcgcgacagggctatacgcatcgggatgtattgactcgtcaaaagttt 
 L  Y  Y  C  A  R  Q  G  Y  T  H  R  D  V  L  T  R  Q  K  F  
tacttctactacatggacgtctggggcaaagggaccacagtcatcgtctcctcagcctcc 
 Y  F  Y  Y  M  D  V  W  G  K  G  T  T  V  I  V  S  S  A  S  
accaagggcccatcggtcttccccctggcgccttgctccaggagcacctccgagagcaca 
 T  K  G  P  S  V  F  P  L  A  P  C  S  R  S  T  S  E  S  T  
gcggccgcatccgcacatcatcatcaccatcacaagctggactacaaagaccatgacggt 
 A  A  A  S  A  H  H  H  H  H  H  K  L  D  Y  K  D  H  D  G  
gattataaagatcatgacatcgattacaaggatgacgatgacaggtataaaagcctt 
 D  Y  K  D  H  D  I  D  Y  K  D  D  D  D  R  Y  K  S  L   
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4. SDS-PAGE and western blot of the expressed antibodies  
    (pSANG-011, 1-1, 1-5, 1-7, 2-1, 2-2, 2-4, I3, I4 and M5) 
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